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PURPOSE AND PLAN OF WORK 
PURPOSE OF WORK 
¾ Glipizide is a second generation of sulphonyl urea for lowering 
blood glucose, due to its short half-life (2 to 5 hrs) and extensive 
protein binding nature (98-99%) that makes Glipizide an ideal 
candidate for controlled release formulations. 
¾ The general oral formulation of glipizide is usually absorbed in the 
gastrointestinal tract quickly and completely, which leads to an 
immediate action of lowering blood glucose and a probable side 
effect of hypoglycemia. However, an oral controlled release 
formulation facilitates the administration, particularly administration 
just once a day, to control the blood glucose concentration at a 
constant level, which results in better compliance by patients and 
fewer side effects. 
¾ The main aim of the work is to achieve time-controlled 
disintegration with distinct predetermined time lag. 
¾ To study the effect of formulation of outer shell comprising both 
hydrophobic polymer and hydrophilic excipients on the time lag of 
drug release. 
¾ To find out the suitable weight ratios of hydrophilic excipients, to 
modulate the time lag of time controlled disintegrating tablets. 
Chapter 1  Purpose of Work 
 2
¾ To investigate the influence of the type and amount of excipients 
mixed with micronized EC in the outer shell on the time lag and time 
controlled disintegration or rupturing function of press coated 
tablets. 
¾ To study the drug release kinetics from data obtained through  
in vitro dissolution studies. 
 
PLAN OF WORK 
 The present work was carried out in the following lines: 
¾ Literature survey on Glipizide drug and time controlled release 
dosage forms. 
¾ Analytical methods 
¾ Formulation of time-controlled disintegrating press-coated tablets of 
Glipizide using hydrophilic excipients and hydrophobic polymers. 
¾ Evaluation studies 
¾ Dissolution kinetics 
Chapter 2  Introduction 
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INTRODUCTION 
 
 Tablets may be defined as solid pharmaceutical dosage forms 
containing drug substance with (or) without suitable diluents and prepared 
by either compression (or) molding1. 
 
ADVANTAGES2 
¾ They are unit dosage forms and offer the greatest capabilities of all 
oral dosage forms for the greatest dose precision and the least 
content variability. 
¾ Their cost is lowest of all oral dosage forms. 
¾ They are the lightest and most comfort of all oral dosage forms 
¾ Product identification is potentially simplest and cheapest, requiring 
no additional processing steps when employing an embossed (or) 
monogrammed punch face. 
¾ They may provide the greatest ease of swallowing with the least 
tendency for “hang up” above the stomach, especially when coated, 
provided the tablet disintegration is not excessively rapid. 
¾ They lend themselves to certain special release profile product, 
such as enteric (or) delayed release products. 
¾ They are better suited to large-scale production than other unit oral 
dosage forms. 
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¾ They have the best-combined properties of chemical, mechanical 
and microbiologically stability of all the oral dosage forms. 
¾ Tablet is a tamper proof dosage form. 
 
DISADVANTAGES 
¾ Drugs with poor wetting, slow dissolution properties intermediate to 
large dosages (or) any combination of these features may be 
difficult (or) impossible to formulate and manufacture as a tablet. 
¾ Some drugs resist compression into dense compact, owing to their 
amorphous nature (or) flocculent, low density character. 
¾ Bitter tasting drugs, drugs with an objectionable odour (or) drugs 
that are sensitive to oxygen (or) atmospheric moisture may require 
encapsulation (or) the tablet may require coating. In such cases the 
capsule may offer the best and lowest cost approach.  
 
Properties of tablets 
 The attributes of an acceptable tablet are as follows: 
1. The tablet must be sufficiently strong and resistant to shock and 
abrasion, to withstand handling during manufacture, packaging, 
shipping and use. This property is measured by two tests, the 
hardness and friability tests. 
2. Tablets must be elegant in appearance and must have the 
characteristic shape, color and other markings necessary to identify 
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the product. Markings are usually the monogram (or) logo of the 
manufacturer. 
3. Tablets often have the National Drug Code Compendium of the 
Food and Drug Administration. Another marking that may appear on 
the tablet is a score (or) crease across the face, which is intended 
to permit breaking the tablet into equal parts for the administration 
of half a tablet. However, it has been shown that substantial 
variation in drug dose can occur in the manually broken tablets. 
4. Tablets must be uniform in weight and in drug content of the 
individual tablet. This is measured by the weight variation test and 
the content uniformity test. 
5. The drug content of tablet must be bioavailable. This property is 
also measured by two tests, the disintegration test and the 
dissolution test. 
6. Bioavailability of a drug from a tablet (or) other dosage form is a 
very complex problem and the results of these two tests do not by 
themselves provide an index of bioavailability. This must be done 
by drug levels in blood. 
7. Tablets must retain all of their functional attributes, which include 
drug stability and efficacy. 
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Ideal characteristics of tablet dosage form 
¾ It has its own identity free of chips, cracks, discoloration and 
contamination. 
¾ Should have strength to withstand vigorous mechanical shocks 
encountered in its production, packaging, shipping and dispensing. 
¾ Should have chemical and physical stability. 
 
On the other hand 
a) It must be able to release the medicinal agent in the body in a 
predictable and reproducible manner. 
b) Must have a suitable chemical stability overtime so as not to allow 
alterations of the medicinal agents. 
c) Pre-compression of amorphous powders cause negative effect on 
dissolution and disintegration rates. 
 
TYPES AND CLASSES OF TABLETS3 
 Tablets are classified by their route of administration (or) function, 
by the type of drug delivery system. They represent within that route, by 
their form and method of manufacture. 
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Tablets ingested orally 
1) Compressed tablets (CT) 
2) Multiple compressed tablets (MCT) 
(a) Layered tablets 
(b) Compression coated tablets 
3) Repeat action tablets 
4) Delayed action and enteric coated tablets 
5) Sugar and chocolate-coated tablets 
6) Film coated tablets 
7) Air suspension coated tablets 
8) Chewable tablets 
 
Tablets used in oral cavity 
1) Buccal tablets 
2) Sublingual tablets 
3) Troches, lozenges and dental cones 
 
Tablets used to prepare solution 
1) Effervescent tablets 
2) Dispensing tablets (DT) 
3) Hypodermic tablets (HT) 
4) Tablet triturate (TT) 
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COMPRESSION COATED TABLETS 
 These are compressed tablets made by more than one 
compression cycle1. 
 Recently a compression coated tablet has received increasing 
attention to deliver a drug in a pulsatile fashion rather than in a continuous 
way at predetermined times and/or sites following oral administration. 
 This novel system is not only rate controlled but time controlled to 
deliver the drug when it is required. 
 The compression coated tablet consists of an inner core and an 
outer coating shell. The outer coating material may be compressed on to 
the inner core with a special compression technique. 
 The manufacturing method of this tablet cannot only eliminate the 
time consuming and complicated operation processes but also improves 
the stability of drug by preventing it from moisture. To design a novel 
compression-coated tablet, the outer coating layer is critical in ensuring 
reliable tolerance to reach the predetermined site. 
 These are also referred to as dry-coated are prepared by feeding 
previously compressed tablet into a special tabletting machine and 
compressing another granulation layer around the preformed tablets. 
 An example of a press-coated tablet press is the manesty drycota. 
Drycota4: In 1937 Killion, a German inventor received a British patent for a 
unit which compressed tablets on one machine and held them in the upper 
punches. These punches had rods passing lengthwise through them. The 
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compression wheel was recessed so that it could compress the cores 
without activating the core rod. The cores were carried around the turret to 
the transfer mechanism. At this point the upper punches passed under a 
roller which pressed down the core rods, to the coating machine. It is 
evident that the manesty drycota adopted the idea of two machines 
running synchronously from this patent. 
 
Advantages 
1) They have all the advantages of compressed tablets i.e. slotting 
monogramming, speed of disintegration. 
2) Masking the taste of the drug substance in the core tablets. 
3) Used to separate incompatible drug substances. 
4) Means of giving an enteric coating to the core tablets. 
5) Widely used in prolonged dosage forms. 
 
Tabletting methods1 
 The three basic methods for the preparation of compressed tablets 
are 
1) Wet granulation method 
2) Dry granulation method 
3) Direct compression 
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Direct compression 
• In spite of enormous improvements in wet granulation techniques 
high shear granulation, fluid bed granulation, continuous granulation 
and all in one granulation; tablet production by direct compression 
has increased steadily over the years because it offers economic 
advantage through its elimination of wet granulation and drying 
steps. 
• The granulation technique that uses slugging (or) roller compaction 
is no longer a method of choice to produce compressed tablets. 
• Direct compression consists of compressing tablets directly from 
powdered material without modifying the physical nature of material 
itself. It involves only two operations, in sequence, powder mixing 
and tabletting. 
 
Advantages4 
1) The most obvious advantage is economy. Saving can occur in a 
number of areas including reducing process, time and thus reduced 
labour cost, fewer manufacturing steps and fewer equipments. 
2) Another advantage is in terms of tablet quality are that is processing 
without the need of moisture and heat. 
3) Optimization of tablet disintegration in which each primary drug 
particle is liberated from and available for dissolution. 
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4) Fewer chemical stability problems would occur in direct 
compression. 
5) In direct compression, the disintegrate is able to perform optimally 
and when properly formulated tablet made by direct compression 
should disintegrate rapidly to primary particles. 
 
Requirements for directly compressible filler binder are: 
 High compactability to ensure that the compacted mass will remain 
bonded after the release of the compaction pressure. 
 Most directly compressible filler binders have undergo physical 
modification in order to improve tabletting properties mainly 
compactability, flowability and apparent density. 
 Good blending properties in order to avoid segregation. 
 Most directly compressible materials are prepared by crystallization. 
The crystal size and in part the crystal shape are selected by 
sieving (or) in some cases after grinding. 
 
Excipients used in direct compression 
 The various forms of cellulose used in direct compression are 
microcrystalline cellulose which is described in the NF of a purified partially 
depolymerized cellulose and powdered cellulose NF which is a purified 
mechanically disintegrated cellulose. 
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MCC (Avicel) 
 Most widely used as a direct compression tablet filler. 
 This inert diluents can have the function of disintegrate binder. 
 Compatible with other excipients and other active ingredients. 
 
Properties 
¾ High dilution capacity 
¾ Low lubricant requirements 
¾ High compressibility 
¾ Fast disintegration 
¾ These have low bulk density which imparts high covering power as 
well as broad particle size distribution which allows optimum 
packaging density. 
¾ It has very low coefficient of friction and therefore has no lubricant 
requirement of itself. 
¾ The reason for the fast disintegration of MCC compacts is the 
immediate disruption of hydroxyl bonds when tablet disintegrates in 
water, since the MCC allows quick penetration of the water by the 
tablet. 
¾ Relatively high expensive material when used as diluents in high 
concentration and thus is typically combined with other materials. 
¾ Therefore MCC be used together with dibasic calcium phosphate as 
the best combination to produce a versatile direct compression 
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vehicle with good flow that yields tablets of high tensile strength, 
friability and fast disintegration. 
 
Starch 
 Commonly the starch source consists of two polysaccharide 
amylase and amylopectin that are based on a glucose monomer. In a 
study about tabletting properties of potato, corn, wheat and barley starch, 
corn starch was best in compactability where as potato starch was best 
with respect to flowability. Modified corn starch is also used as an 
excipient in direct compression is marked as sepistab ST 200 which is of 
particle size 300 µm and has good compactability and lubricant properties. 
 
Inorganic salts 
o Di-calcium phosphate di-hydrate is the most commonly used 
inorganic salt filler binder. 
o Di-tab is brand of unmilled di-calcium phosphate di-hydrate where 
as Em-compress is a unique form of di-calcium phosphate  
di-hydrate in which particle size distribution is controlled to ensure 
flowability. 
o An advantage of using di-calcium phosphate in tablets for vitamin 
(or) mineral supplement is the high calcium and phosphorous 
content. 
o Brittle in nature. 
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o Tricalcium phosphate can be used as a filler binder in direct 
compression and as filler in tablets prepared by new granulation. 
o Direct compression grades of sorbitol can be used for the 
production of lozenges, chewable tablets and disintegrating tablets. 
The inclusion of pregelatinized starch in sorbitol tablet can prevent 
recrystallization and increase in tablet crushing strength. 
o Tablets compressed from lactose monohydrate without a lubricant 
disintegrate very quickly in water as a result of rapid liquid uptake 
and fast dissolution of the bonds. The presence of hydrophobic 
lubricant has a strong inhibiting effect on water penetration and 
hence on disintegration time. This effect can be easily counteracted 
by the addition of microcrystalline cellulose (or) high swelling 
disintegrate such as sodium starch glycolate (or) croscarmelose 
sodium. 
o Sucrose is commonly used in modified form that makes it more 
efficient for direct compression. The modified form is known as 
compressible sugar NF XVII. Nutab from ingredient technology 
contains sucrose about 4% invert sugar and small percentages of 
corn starch and magnesium stearate. 
o Mendes et al. evaluated NU-tab as a chewable filler binder for direct 
compression in combination with several active ingredients and 
1.0% magnesium stearate. Generally good tablets could be 
prepared with NU-tab. 
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o When compared the performances of food grade of hydrous and 
anhydrous dextrose with spray dried lactose as an excipient in 
direct compression tablets, the result indicates that hydroxyl 
dextrose can be partly (or) completely substituted for spray dried 
lactose in some formulations. Dextrose was found to give less 
browning than spray dried lactose in formulation containing no 
amines, more browning was observed in the presence of amines. 
 
Co-processed products 
 Excipient mixtures are generally produced to make use of the 
advantages of each component and to overcome specific disadvantages. 
The functionality of excipient mixtures is enhanced by a special process by 
which mixtures are combined. The excipient mixtures used in direct 
compression have added value compared to physical mixture of 
excipients. For this reason ready to use blends for direct compression 
were offered from different suppliers, most important are the binding and 
blending properties of the co-processed excipients which must be better 
than those of physical mixture of the starting materials. Cost is another 
factor to consider in the selection of combination products. Other 
examples of co-processed products are indipress cellactose and 
pharmatose DCL 40. 
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A SYSTEMATIC AND MODERN APPROACH TO TABLET PRODUCT 
DESIGN5 
 Tablet product design requires two major activities. First, 
formulation activities begin by identifying the excipients most suited for a 
prototype formulation of the drug. Second, the levels of those excipients in 
the prototype formula must be optimally selected to satisfy all 
process/product quality constraints. 
 
Factors affecting the type of excipients used in a tablet formula 
 The type of excipient used may vary depending on a number of 
preformulation, medical, marketing, economic and process/product quality 
factors as discussed in the following sections. Here we mainly focus on the 
process/product quality. 
 
Typical tests performed on tablets are as follows: 
¾ Weight variation 
¾ Hardness 
¾ Friability 
¾ Disintegration time 
¾ Dissolution 
¾ Water content 
¾ Potency 
¾ Content uniformity 
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 Product quality is most often assessed at the tablet development 
stage. However, it is also important to monitor the processing quality of a 
formulation during development. They are 
a. To optimize the process as well as the product. 
b. To establish in-process quality control tests for routine production. 
 It is more difficult to quantify the processing quality of a formulation 
than it is to measure the product quality. Some measurements that could 
be performed on the process include: 
¾ Ejection force 
¾ Capping 
¾ Sticking 
¾ Take-off force 
¾ Flow of lubricated mixture 
¾ Press speed (maximum) 
¾ Frequency of weight control adjustments 
¾ Sensitivity of formula to different presses 
¾ Tooling wear 
¾ Effect of consolidation load (batch size) 
¾ Hopper angle for acceptable flow 
¾ Hopper orifice diameter for acceptable flow 
¾ Compression forces 
¾ Environment conditions (temperature, humidity, and dust) 
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 Each of the above processing parameters can become a source of 
trouble in scale-up (or) routine production. By monitoring these parameters 
in development, it may be possible to adjust the formula (or) process early 
enough to alleviate the source of trouble. The expected production output 
(number of tablets) per unit time will determine what speed tablet press will 
be required for a particular tablet product. If the anticipated unit output for 
a tablet product is expected to be large, a high-speed press will be 
required. 
 Attempts should be made in formulation development to design a 
tablet formula that will perform well on a high-speed press. A formula to 
run on a high-speed press should have excellent flow to maintain uniform 
die fill during compression. It should have good bonding characteristics so 
that it can compress with a minimal dwell time. 
1. Environmental conditions ambient (or) humidity control 
2. Stability of the final product 
3. Bioavailability of the active drug content of the tablet. 
 The selection of excipients is critical in the formulation of tablets, 
once the formulator has become familiar with the physical and chemical 
properties of drug. The process of selecting excipients has begun. The 
stability of the drug should be determined with each proposed excipient. 
 This can be accomplished as follows: 
 In the laboratory, prepare an intimate mixture of the drug with an 
excess of each individual excipient and hold at 60°C for 72 hr in a glass 
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container. At the end of this period analyze for the drug using a stability 
indicating assay. 
 
DIFFERENT ADJUVANTS USED IN TABLET FORMULATION 
 In addition to the active or therapeutic ingredient, tablets contain a 
number of inert materials called as additives or excipients. They may be 
classified according to the part they play in the finished product. The first 
group contains those that help to impart satisfactory processing and 
compression characteristics to the formulation which includes diluents, 
binders, glidants and lubricants. The second group of added substances 
helps to give additional desirable physical characteristics to the product. 
They include disintegrants, colors, flavors, sweetening agents. 
 
Diluents or fillers4 
 These are inert substances which will increase the bulk of the 
tablet. Selecting the diluents is an important character while tabletting. 
These agents may not be necessary if the dose of the drug per tablet is 
high. Generally a tablet should weigh at least 50mg and therefore very low 
dose drugs will invariably require diluents to bring the overall tablet weight 
to at least 50mg. 
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Diluents or fillers fall into two general categories 
1. Carbohydrate and modified carbohydrate excipients. 
2. Inorganic materials 
 In wet granulation process, such carbohydrate substances as 
sugars, starches and cellulose may also function as binder, whereas in 
direct compression systems, they serve as diluents carrier. The inorganic 
excipients, when used in either system, are not a binder, which is a 
cohesive agent in directly compressible system. Hence they function more 
as a carrier. 
 Microcrystalline cellulose (MCC) (AVICEL) is most widely used as 
direct compression tablet filler. It has a function of disintegrant besides that 
of a dry binder and is compatible with most excipients and active 
ingredients. 
 Lactose is inexpensive, soluble and easily granulated diluents, 
because it lacks flowability and compressibility in its common form. 
Lactose in modified form can only be used in direct compression. 
 The other commonly used diluents are mannitol, Kaolin, dry starch, 
calcium sulfate, dicalcium phosphate. 
 
Binders or Adhesives6 
 Binders are solid materials in the manufacture of solid dosage 
forms because of their adhesive and cohesive properties. Their role is to 
assist size enlargement by adding cohesiveness to powders, thereby 
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providing granules and tablets with necessary bond strength, they improve 
the appearance, hardness and friability of preparations, but are not 
intended to influence the dissolution or disintegration of active substances. 
 Binders are starch, gelatin, sugars or polymeric substances. The 
later fall into two classes: 
a) Natural polymers such as starches or gum including acacia, 
tragacanth, gelatin. 
b) Synthetic polymers such as polyvinyl pyrrolidone, methyl and ethyl 
cellulose and hydroxypropyl cellulose. 
c) The quantity of binder used has a considerable effect on the 
characteristic of the compressed tablets. The use of too much 
binder or too strong binder will make a hard tablet that will not 
disintegrate easily. Binders are used both as solution and in dry 
form, depending on other ingredients in the formulation and method 
of preparation. However pregelatinised starches available are 
intended to be added in dry form so that water alone can be used 
for granulating solution. 
 The direct compression method for preparing tablets requires a 
material that is not only free flowing but also sufficiently cohesive to act as 
a binder. For this microcrystalline cellulose, amylase and polyvinyl 
pyrrolidone is used. 
 MCC is a non fibrous form of cellulose. It is water insoluble but has 
the ability to draw fluid into tablet by capillary action. It swells on contact 
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and thus acts as disintegrating agent. The material flows well and has a 
degree of self lubricating qualities. 
 Starch paste is a common binder. Starch extracted from maize, 
potato, rice, wheat is widely used as tablet binder. It has a concentration 
between 5 and 25%. It produces relatively soft and friable granules and 
tablets disintegrate readily. High viscosity is its drawback. Pregelatinized 
starch can be used instead of starch paste. 
 
Disintegrants 
 Disintegrants is the term applied to various agents added to tablet 
granulation for the purpose of causing the compressed tablet to break 
apart (disintegrate) when placed in aqueous environment. Basically the 
disintegrants' major function is to oppose the efficiency of tablet binder and 
the physical forces that act under compression to form tablet. The stronger 
the binder, the more effective must be the disintegrating agent in order for 
the tablet to release its medication. Ideally it should cause the tablet to 
disrupt, not only into the granules from which it was compressed, but also 
into the powder particle from which the granulation was prepared. 
 There are two methods used for incorporating disintegrating agents 
into the tablet: 
1) External addition 
2) Internal addition 
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 In this, the disintegrant is added to the sized granulation with mixing 
just prior to compression. In the internal addition method, the disintegrant 
is mixed with some other powders before wetting the powder mixture with 
granulating solution. Thus, the disintegrant is incorporated within the 
granule. When this method is used, part of the disintegrant can be added 
internally, and part externally. This provides immediate disruption of tablet. 
 
Disintegrants act by different mechanisms 
1. They enhance action of capillaries in producing a rapid uptake of 
aqueous fluids: E.g. starch, microcrystalline cellulose. 
2. Those that swell on contact with water E.g. Sodium starch 
glycolate, carboxy methylcellulose. 
3. That release has to disrupt the tablet structure. E.g. certain 
peroxides. 
4. That destroys the binder by enzymatic action. E.g. starch amylase. 
The other mechanisms like heat of wetting also exist. 
 Disintegrants constitute a group of material that on contact with 
water, swell, hydrate, change in volume or form, or react chemically to 
produce a disruptive change in tablet. These groups include various forms 
of starch, cellulose, bentonite, aligns, vegetable gums, clays, ion exchange 
resins and acid base combinations. Carboxy methyl cellulose, corn and 
potato starch are popular disintegrants. They have great affinity for water 
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and swell when moistened, then facilitating, the rupture of tablet matrix. 
Starch usually 5 to 15% is used. 
 A group of materials known as superdisintegrants have gained 
popularity. Croscarmelose, crospovidone and sodium starch glycolate 
represent examples of a cross linked cellulose, a cross linked polymer and 
cross linked starch respectively. 
 Sodiumlauryl sulphate in combination with starch is an effective 
disintegrant. In some cases the effectiveness of surfactants in improving 
tablet disintegration is postulated as due to an increase in the rate of 
swelling. 
 The binder, tablet hardness, lubricants can also affect disintegration 
time. 
 
Glidants1 
 Glidants improve the flow characteristics of the powder mixture. 
These materials are added in the dry state just prior to compression. 
Colloidal silicon dioxide is the most commonly used glidant and generally 
used in low concentration of 1% or less. Talc is also used and may serve 
the dual purpose of glidant/lubricant. 
 It is important to optimize the order of addition and mixing process 
of these materials to maximize their effect and to make sure that their 
influence on lubricants is minimized. 
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Lubricants 
 They have a number of functions in tablet manufacture. 
1. They prevent adhesion of the tablet material to the surface of the 
dies and punches. 
2. Reduce interparticle friction. 
3. Facilitate the ejection of tablets from the die cavity. 
4. Improves the rate of flow of tablet granulation. 
 Commonly used lubricants include talc, magnesium stearate, 
calcium stearate, stearic acid, hydrogenated vegetable oils. Most 
lubricants are used in concentration below 1% when used alone. Talc is 
used in concentration as high as 5%. Lubricants are mostly hydrophobic 
materials. Poor selection or excessive amounts can result in waterproofing 
the tablets, resulting in poor tablet disintegration and/or delayed 
dissolution of drug substance. 
 
Antiadherents 
 These are useful in formulation, which have a tendency to pick 
easily. Multivitamin products containing high vitamin E levels often display 
extensive picking which can be minimized through the use of colloidal 
silica such as syloid (0.1 to 0.5). 
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Adsorbents 
 Adsorbents are substances included in a formulation that are 
capable of holding quantities of fluids in an apparently dry state. Oil 
soluble drug fluid extractors (or) oils can be mixed with adsorbents and 
then granulated and compressed into tablet. E.g. fumed silica, 
microcrystalline cellulose, magnesium carbonate, Kaolin, bentonite, etc. 
 
Coloring agents 
 Color helps the manufacturer to control the product during its 
preparation, as well as serving as means of identification to the users. 
All colorants used in pharmaceuticals must be approved by FDA. Lake is 
the combination of a water soluble dye to a hydrous oxide of a heavy 
metal resulting in an insoluble form of the dye. The most common method 
of adding color to a tablet formulation is to dissolve the dye in the binding 
solution prior to the granulating process. Migration of colors may be 
reduced by drying the granules slowly at lower temperature and stirring the 
granules while it is drying. 
 Different colorants used are D and C Red 33, iron oxide, red- 
caramel, titanium oxide, cochineal extract. 
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Sweetening agents 
 In addition to the sweetness which may be afforded by the diluents 
of the chewable tablet. E.g. Mannitol (or) Lactose. Sweeteners other than 
sugar that have an advantage of reducing the bulk volume are cyclamates, 
saccharin, aspartame (Searle). 
 
Surfactants 
 Molecules (or) ions that are adsorbed at interfaces are termed as 
surfactants. Depending on the number and nature of the polar and non-
polar groups present, the amphiphile may be predominantly hydrophilic 
suggesting that the molecules (or) ion have a certain affinity for both polar 
and non-polar solvents. 
 The hydrophilic portion of the surfactant is soluble in the polar 
solvent and the lipophilic portion is soluble in the non-polar solvent. The 
surfactant occupies the interface to decrease interfacial tension and 
thereby increases the solubility. Release of poorly soluble drugs from 
tablet and hard gelatin capsules may be increased by the inclusion of 
surfactants in the formulations. 
 
PRODUCTION OF TABLETS3 
 Tablets are made by compressing the formulation containing a drug 
or drugs with excipients on stamping machines called presses. Tablet 
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compression machine or tablet presses are designed with the following 
basic components: 
1) Hoppers for holding and feeding granulation to be compressed. 
2) Dies that define the size and shape of the tablet. 
3) Punches for compressing the granulation within the dies. 
4) Cam tracks for guiding the movement of the punches. 
5) A feeding mechanism for moving granulation from the hopper into 
the dies. 
 
Punches and Dies 
 They are usually fabricated from special steels, the working surface 
being accurately machined and highly polished to ensure proper 
mechanical operation and well finished tablets. 
 Punches and dies (tooling) must be stored, lightly oiled, in 
containers which prevent accidental contact. The ease of manufacture and 
the final appearance of the tablet depend on unblemished, highly polished 
working surfaces. Punch edges must be sharp and free from burrs. 
 
Operation 
 Once the machine has been assembled, trial tablets may be made 
with the press. The optimum tablet hardness depends on the material to 
be compacted and the ultimate use of the tablets. 
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 As the head of the press rotates, the punches are guided up and 
down by fixed cam tracks, which control the sequence of filling, 
compression and ejection. The portions of the head that hold the upper 
and lower punches are called the upper and lower turrets respectively and 
the portion holding the dies is called the die table. At the start of a 
compression cycle, granulation stored in a hopper empties into the feed 
frame which has several interconnected compartments. These 
compartments spread the granulation over a wide area to provide time for 
the dies. The pull down cam guides the lower punches to the bottom of 
their vertical travel, allowing the dies to overfill. The punches then pass 
over a weight control cam which reduces the fill in the dies to the desired 
amount. A wipe off blade at the end of the feed frame removes the excess 
granules and directs it around the turret and back into the front of the feed 
frame. Next the lower punches travel over the lower compression roll, 
while simultaneously the upper punches ride beneath the upper 
compression roll. The upper punches enter a fixed distance into the dies, 
while the lower punches are raised to squeeze and compact the 
granulation within the dies. After the movement of compression, the upper 
punches are withdrawn. The lower punches ride up the cam which brings 
the tablets flush with or slightly above the surface of the dies. The tablet 
strike a sweep-off blade affixed to the front of the feed frame and slide 
down a chute into a receptacle. At the same time the lower punches 
reenter the pull down cam and the cycle is repeated. 
Chapter 2  Introduction 
 30
SITE SPECIFIC DELIVERY 
 Most drugs - whether taken orally (or) via injection are delivered to 
the body system-wide (systemically). The medication circulates throughout 
the body affecting organs and cells that are dysfunctional as well as those 
that are healthy. Because systemic drug delivery floods the body with 
medication, it can sometimes cause serious side effects. 
 Advantages in medical device technology such as the development 
of fully implantable infusion systems now allow for site-specific drug 
delivery. Site specific drug delivery is preferred when higher regional drug 
levels can be obtained as compared to those of other routes of 
administration. A resultant benefit is reduced (or) eliminated side effects 
related to high systemic drug levels. 
 Direct infusion of medication into the largest organ (or) blood 
vessels supplying those organs goes directly to the site in the body that 
needs it most site specific drug delivery allows for higher drug 
concentrations, increase quality of life for patients and in some cases 
extend lives. 
⇒ Site specific drug delivery has several distinct advantages over 
other means of delivering drugs. For example direct infusion into 
the target organ (or) vasculature surrounding and supplying blood 
to the organ ensures that the majority of drug goes to the site it is 
intended to act on. This allows for the use of more toxic drug 
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against (e.g. Chemotherapeutic) in high concentrations because the 
exposure of other organs to the compound is limited. 
⇒ Site specific drug delivery7 requires completion of several 
sequential but independent events. These include localization of 
drug and carrier within the desired target organ, recognition and 
interaction of the carrier with specific target cell(s) and delivery 
therapeutic concentration of drug to the target cell(s) with little (or) 
no uptake by non-target (normal) cells. 
 Site specific drug delivery can be classified according to the level of 
specificity achieved in the delivery process: 
1. Delivery to individual organs (or) tissues (organ targeting) 
2. Targeting to a specific cell type(s) with a tissue (cellulose targeting). 
3. Delivery to different intracellular compartments in target cells by 
engineering the internalization of drug and drug carrier construct via 
specific transport pathways (intracellular targeting) 
 However the role of carrier systems in providing site specificity can 
be evident from the terms like “Passive and Active” targeting approaches. 
 Passive targeting involves therapeutic exploitation of the natural 
(intrinsic / inherent) distribution pattern of a drug-carrier construct in vivo. 
For example the role of the reticulo endothelial system (RES) in cleaning 
foreign particulate materials from the blood permits drug encapsulated in 
particulate materials from the blood permits drug encapsulated in 
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particulate carriers like liposome and microspheres to be passively 
targeted to macrophages. 
 In contrary “active targeting” is aimed at altering the natural 
distribution pattern of drug-carrier construct either away from RES (long 
circulatory) or to the specific cells, tissues (or) organs (liquid intervention). 
 
Optimized drug delivery8 
¾ This can be achieved by targeted prodrug design. 
¾ Site selective targeting with prodrugs to a specific enzyme (or) 
specific membrane transporter, or both, has potential as a selective 
drug delivery system in cancer chemotherapy (or) as an efficient 
oral drug delivery system. 
¾ On the other hand targeted prodrug design represents a new 
strategy for directed and efficient drug delivery. 
¾ Site specific drug delivery can be achieved by the enzyme-targeted 
prodrug. 
¾ In prodrug design enzymes can be recognized as systemic 
metabolic sites (or) prodrug-drug in vivo reconversion sites. 
 
Strategy for site-specific drug delivery 
 The use of prodrugs has been actively pursued to achieve very 
precise and direct effects at the “site of action” with minimal effect 
on the rest of the bodies. 
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 Stella and Himmelstein suggested that at least 3 factors should be 
optimized for site specific delivery of drugs by using prodrug 
approach. 
1. The prodrug must be readily transported to the site of action, and 
uptake to the site must be rapid and essential perfusion rate limited. 
2. Once at the site, the prodrug must be selectively cleaved to the 
active drug relative to its conversion at other sites. 
3. Once selectively generated at the site of action, the active drug 
must be somewhat retained by the tissue. 
 In the prodrug approach, site-specific drug delivery can be obtained 
from tissue-specific activation of a prodrug, which is the result of 
metabolism by an enzyme. That is either unique for the tissue (or) present 
at a higher concentration (compared with other tissues), thus it activates 
the prodrug more efficiently. 
 For example, glycosidase activity of colonic micro flora offers 
opportunities to design colon-specific drug derivatives are hydrophilic and 
poorly absorbed from the small intestine, but once they reach the colon, 
they can be effectively cleaved by bacterial glycosidase to release the free 
drug or be absorbed by the colonic mucosa. 
 Site-specific (or) targeted delivery involves drug delivery to a 
specific organ (or) class of cells (or) physiological compartment. Site-
specific drug delivery can be aimed at systemic absorption (or) for local 
effects. 
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 Various site-specific oral controlled release systems have been 
developed, depending upon the target site which can be classified as 
I. Systems targeted to duodenum/stomach 
II. Systems targeted to small intestine 
III. Systems targeted to lymphatic 
IV. Systems targeted to colon 
 
1. Systems targeted to stomach/duodenum 
 These types of system not only prolong the stomach residence 
time, but also in the area of the GI tract such that the active ingredients 
reach their optimum absorption site in solution and are ready for 
absorption. These type of systems are used with 
⇒ Drugs insoluble in intestinal fluid. 
⇒ Drugs exerting its therapeutic action in stomach / duodenum E.g. 
antacids such as oxides, hydroxides and carbonates of magnesium, 
aluminum hydroxides and magnesium trisilicate. 
⇒ Drugs exhibiting site specific absorption from duodenum E.g. 
chlorphenaramine maleate. 
⇒ Drugs absorbed significantly from stomach e.g. certain vitamins 
(Vit. B and Vit C) and minerals. 
⇒ Highly acidic drugs e.g. aspirin produce irritation on contact with 
stomach wall, which can be prevented by these types of systems. 
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Different systems used for stomach/duodenum targeting are 
a) Hydrodynamically balanced systems (low density formulations) 
b) Air entrapped systems 
c) Size-based systems 
d) Bioadhesive systems 
 
2. Systems targeted to small intestine 
 These systems are made such that they permit the safe passage of 
a system through the acid environment of the stomach to more suitable 
juices of the intestines. 
 These type of systems used with 
⇒ Drugs destroyed by gastric acid e.g. enzymes and some antibiotics 
e.g. Erythromycin 
⇒ Drugs irritating to gastric mucosa, e.g. sodium salicylate. 
⇒ Drugs which are required at intestine for local action, e.g. intestinal 
antiseptics 
 Systems for intestinal targeting are 
(a) Enteric coated tablets 
(b) Bioadhesive systems 
 
3. Systems targeted to lymphatic 
 The intestinal lymphatic system consists of a network of vessels 
throughout the small and large intestine which are involved in the potential 
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uptake of particulates administered orally of nanometer and micrometer 
size range. These lymphatic play a major role in the absorption of a variety 
of nutrients, lipids, fluids and drugs. 
 These systems are used for the following purposes: 
1. Avoidance of hepatic first pass metabolism. 
2. Selective treatment of diseases and infections of mesenteric 
lymphatic. 
3. Enhanced absorption of large molecules of higher weight, such as 
peptides and particulates. 
4. Inhibition of cancer cell metastasis. 
5. Drugs susceptible to chemicals and/or enzymes in luminal fluids. 
6. Drugs which are highly hydrophilic and ionizable at all pH values as 
streptomycin, gentamycin and vanomycin. 
7. Drugs which are highly hydrophobic. 
8. Drugs exhibiting poor and unpredictable bioavailability. 
9. Oral administration of antigens. 
 
Different systems used for lymphatic targeting 
(1) Lipidic systems 
(2) Polymeric systems 
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4. Systems targeted to colon 
 Drug delivery selectively to the colon through the oral route has 
been the subject of new research initiatives. Drug release is delayed until it 
enters the colon. This approach utilizes colonic micro flora and colonic pH 
as in-house mechanism for selective drug release and its absorption at the 
colon. 
 Although the system needs wider study before its regular 
implementation in drug delivery. 
 These types of system are used for 
9 Drugs used for local effects in colon for inflammatory bowel 
diseases (E.g. ulcerative colitis and Crohn’s disease), irritable colon 
syndrome, infectious diseases and colon cancer for effective and 
safe therapy. E.g. 5-amino salicylic acid, mebeverine hydrochloride, 
sulphasalazine, hydrocortisone acetate, 5-flourouracil, dozorubicin, 
nimustine. 
9 Drugs which are poorly absorbed orally, as colon has longer 
residence time and is highly responsive to agents that enhance the 
absorption of poorly absorbable drugs. 
9 For the avoidance of hepatic first pass metabolism of drugs. 
9 Where the delay in system absorption is therapeutically desirable, 
especially in diseases susceptible to diurnal variation. 
9 Some orally administered drugs which exhibit poor uptake in upper 
GI tract (or) show enzymatic degradation, can be investigated for 
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better bioavailability through colon. E.g. metoprolol, nifedipine, 
isosorbide, brompheniramine, diclofenac, ibuprofen. 
 Drug delivery systems targeted to colon can be broadly classified 
as: 
¾ pH based drug delivery systems 
¾ Enzyme based systems 
¾ Prodrugs based drug delivery system 
¾ pH independent biodegradable polymer based drug delivery 
systems. 
 
Advances 
⇒ Two advances in medical technology have allowed the 
development of new strategies for site-specific delivery of medication. 
1. First, the ability to place and manage indwelling catheters in the 
vascular space (e.g. hepatic artery for liver tumors, (or) metastases) 
and in the spinal space (for the management of intractable pain and 
other central nervous system disorders). 
2. Second, the development of reliable, totally implantable drug 
pumps. 
⇒ Site-specific drug delivery can offer significant advantages for some 
patients in the later stages of the disease, for example in the case 
of hepatic arterial infusion (HAI) therapy for treatment of metastatic 
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colon cancer, it is known that these tumors receive an estimated 
80% of their blood supply from the hepatic artery. 
⇒ Site-specific delivery of chemotherapy is not new, but early 
experiments required patients to be hospitalized for the procedure. 
External catheters were placed through the skin, increasing the risk 
for infection. The development of fully implantable, continuous 
infusion pumps allow patients to be mobile and reduces the need 
for inpatient clinic visits for drug infusion. These pumps also have 
the advantage of requiring little (or) no home care. Patients often 
can participate in activities of daily living, as their illness permits, 
with little hindrance from side effects (or) administration of drugs. 
⇒ Site specific delivery is cost effective when compared with medical 
management (e.g. oral medications, physic or psychotherapy, use 
of resources, site-specific drug delivery for the treatment of chronic 
pain pays itself in about two years of treatment. Medical condition, 
stage of illness, and other disease related criteria determine 
candidates for site-specific drug delivery. As with any medical 
treatment, patients should talk with their doctors about the risks 
involved. For example, because the pump and catheter are 
surgically placed, infections are possible. The catheter could 
become dislodged or blocked. These events, while rare, could 
cause a reduction in (or) loss of therapeutic effect. 
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 Drug related side effects also can occur. 
 Site specific drug delivery is an exciting disease management 
alternative for appropriately selected patients, offering potentially and life-
enhancing benefits. 
 
CONTROLLED RELEASE TECHNOLOGY7 
 Conventional drug therapy typically involves the periodic dosing of a 
therapeutic agent that has been formulated in a manner to ensure its 
stability, activity and bioavailability. For most of the drugs, conventional 
methods of formulation are quite effective. However some drugs are 
unstable and toxic and have a narrow therapeutic range, exhibit extreme 
solubility problems, require localization to a particular site in the body or 
require strict compliance or long term use. In such cases a method of 
continuous administration of drug is desirable to maintain fixed plasma 
drug levels. The goal in designing sustained or controlled delivery systems 
is to reduce the frequency of the dosing or to increase effectiveness of the 
drug by localization at the site of action, reducing the dose required to 
providing uniform drug delivery. So, controlled release dosage form is a 
dosage form that release one or more drugs continuously in a 
predetermined pattern for a fixed period of time, either systemically or to a 
specified target organ. Controlled release dosage forms provide a better 
control of plasma drug levels, less dosage frequency, less side effect, 
increased efficacy and constant delivery. 
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Terminology9 
 Modified release delivery systems may be divided conveniently into 
four categories. 
A) Delayed release 
B) Controlled release 
1 Sustained release 
2 Extended release 
C) Site specific targeting 
D) Receptor targeting 
 
A) Delayed Release 
 These systems are those that use repetitive, intermittent dosing of a 
drug from one or more immediate release units incorporated into a single 
dosage form. 
 Examples of delayed release systems include repeat action tablets 
and capsules and enteric-coated tablets where timed release is achieved 
by a barrier coating. 
B) Controlled release 
 These systems also provide a slow release of drug over an 
extended period of time and also can provide some control, whether this 
be of a temporal or spatial nature, or both, of drug release in the body, or 
in other words, the system is successful at maintaining constant drug 
levels in the target tissue or cells. 
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1) Sustained release 
 Pharmaceutical dosage forms that release the drug slower than 
normal manner at predetermined rates and necessarily reduce the dosage 
frequency by two folds. 
2) Extended release 
 These systems include any drug delivery system that achieves slow 
release of drug over an extended period of time. 
C) Site specific targeting 
 These systems refer to targeting of a drug directly to a certain 
biological location. In this case the target is adjacent to or in the diseased 
organ or tissue. 
D) Receptor targeting 
 These systems refer to targeting of a drug directly to a certain 
biological location. In this case the target is the particular receptor for a 
drug within an organ or tissue. 
 Site specific targeting and receptor targeting systems satisfy the 
spatial aspect of drug delivery and are also considered to be controlled 
drug delivery systems. 
 
Potential advantages of controlled drug therapy10 
 All controlled release products share the common goal of improving 
drug therapy over that achieved with their non-controlled 
counterparts. This improvement in drug therapy is represented by 
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several potential advantages of the use of controlled release 
systems as mentioned below. 
A) Avoid patient compliance problems. 
B) Employ less total drug 
 Minimize or eliminate local side effects. 
 Minimize or eliminate systemic side effects. 
 Obtain less potentiation or reduction in drug activity with 
chronic use. 
 Minimize drug accumulation with chronic dosing. 
C) Improves efficiency in treatment 
 Cure or control condition more promptly 
 Improves control of condition i.e. reduce fluctuation in drug 
level. 
 Improves bioavailability of some drugs. 
 Make use of special effects e.g. sustained release aspirin for 
morning relief of arthritis by dosing before bedtime. 
D) Economy 
 
Limitations of Oral CRDDS 
 On the other hand oral CRDDS suffer from a number of potential 
disadvantages: 
 Relatively poor in vitro - in vivo correlation 
 Possible dose dumping 
Chapter 2  Introduction 
 44
 Reduced potential for dose change or withdrawal in event of toxicity 
 Loss of effect due to diarrohea (too fast transit time) 
 
Reasons for Oral CRDDS 
 There is a clinical need to develop the CR formulations to improve 
drug therapy over that achieved with their conventional counterparts, 
especially in the following cases: 
1. Short elimination half-life (t½) and minimum effective concentration 
(MEC) required for the therapy. Shorter the half life of a drug, larger 
will be the fluctuations between the maximum steady state 
concentration (Cssmax) and the minimum steady state concentration 
(Cssmin) upon multiple dosing. If MEC is therapeutically required, 
either frequent dosing of a conventional drug product or 
development of a CR product is necessary. 
2. Similarly the drugs having reasonably long elimination half life and 
either wide or narrow therapeutic range may also need to be 
formulated as CR products mainly for: 
• Two to three day extension and 
• Minimize the fluctuations between Cssmax and Cssmin with narrow 
therapeutic range drugs. 
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DRUG PROFILE 
DRUG PROFILE11, 12, 13 
Product Name : Glipizide. 
N
NCH3
NH
S
NH
NH
O
O O O
 
Molecular Formula : C21H27N5O4S 
Formula Weight : 445.53518 
Composition : C (56.61%), H (6.11%), N (15.72%), O (14.36%),  
S (7.20%) 
Synonym : 1-cyclohexyl-3-[[4-[2-[[(5-methylpyrazin-2-yl) 
carbonyl]amino]ethyl]-phenyl]sulphonyl] urea. 
  It contains not less than 98.0% and not more than 
102.0% of C21H27N5O4S calculated with reference 
to the dried. 
 
1. PHYSICAL AND CHEMICAL PROPERTIES 
Physical state and  
appearance : Solid. (Solid powder), a white (or) almost 
white, crystalline powder 
Odor : Odorless 
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Molecular weight : 445.55 g/mole 
Melting point : 208.5° C (407.3° F) 
Dispersion properties : Is not dispersed in cold and hot water 
Solubility : Insoluble in cold and hot water 
 
2. STABILITY AND REACTIVITY 
Stability : The product is stable 
Polymerization : No 
 
3. TOXICOLOGICAL INFORMATION 
Routes of Entry : Absorbed through skin. Eye contact. Inhalation. 
Ingestion. 
Carcinogenic effects : Classified None by NTP, None by OSHA, 
None by NIOSH. 
Teratogenic effects : Classified none for human. 
Development toxin : The substance is toxic to blood, liver, 
cardiovascular system, central nervous system 
(CNS). 
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4. CLINICAL PHARMACOLOGY 
4.1. Mechanism of action 
 The primary mode of action of glipizide in experimental animals 
appears to be the stimulation of insulin secretion from the beta cells of 
pancreatic islet tissue and is thus dependent on functioning beta cells in 
the pancreatic islets. In humans, glipizide appears to lower the blood 
glucose acutely by stimulating the release of insulin from the pancreas, an 
effect dependent upon functioning beta cells in the pancreatic islets. 
4.2. Other Effects 
 It has been shown that glipizide therapy was effective in 
controlling blood sugar without deleterious changes in the plasma 
lipoprotein profiles of patients treated for NIDDM. In a placebo-controlled, 
crossover study in normal volunteers, glipizide had no antidiuretic activity, 
and, in fact, led to a slight increase in free water clearance. 
 
5. PHARMACOKINETIC DATA 
Bioavailability : 100% (regular formulation), 90% (extended 
release) 
Protein binding : 98 to 99% 
Metabolism : Hepatic hydroxylation 
Half life : 2 to 5 hrs 
Excretion : Renal and fecal 
Chapter 3 Drug Profile 
 
 48
6. CONTRAINDICATIONS / CAUTIONS 
Contraindicated in patients with 
 : Known hypersensitivity to the drug. 
 : Diabetic ketoacidosis, with or without coma. 
This condition should be treated with insulin. 
Warnings!!! : Special warning on increased risk of 
cardiovascular mortality. 
 
7. ADVERSE REACTIONS 
7.1. Gastrointestinal 
 Diarrohea, one in seventy; constipation and gastralgia, one in one 
hundred. They appear to be dose-related and may disappear on division 
or reduction of dosage. Cholestatic jaundice may occur rarely with 
sulfonylureas, glipizide should be discontinued if this occurs. 
7.2. Dermatologic 
 Allergic skin reactions including erythema, morbilliform or 
maculopapular eruptions, urticaria, pruritus, and eczema have been 
reported in about one in seventy patients. 
7.3. Hematologic 
 Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, 
aplastic anemia, and pancytopenia have been reported with sulfonylureas. 
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7.4. Metabolic 
 Glipizide pretreatment did not cause an accumulation of 
acetaldehyde after ethanol administration. Clinical experience to date has 
shown that glipizide has an extremely low incidence of disulfiram-like 
alcohol reactions. 
7.5. Endocrine Reactions 
Cases of hyponatremia and the syndrome of inappropriate 
antidiuretic hormone (SIADH) secretion have been reported with this and 
other sulfonylureas. 
7.6. Miscellaneous 
 Dizziness, drowsiness, and headache have each been reported in 
about one in fifty patients treated with glipizide. They are usually transient 
and seldom require discontinuance of therapy. 
7.7. Laboratory Tests 
 The pattern of laboratory test abnormalities observed with glipizide 
was similar to that for other sulfonylureas. Occasional mild to moderate 
elevations of SGOT, LDH, alkaline phosphatase, BUN and creatinine were 
noted. One case of jaundice was reported. The relationship of these 
abnormalities to glipizide is uncertain, and they have rarely been 
associated with clinical symptoms. 
 
Chapter 3 Drug Profile 
 
 50
8. DRUG INTERACTIONS 
 The hypoglycemic action of sulfonylureas may be potentiated by 
certain drugs including nonsteroidal anti-inflammatory agents, some 
azoles, and other drugs that are highly protein bound, salicylates, 
sulfonamides, chloramphenicol, probenecid, coumarins, monoamine 
oxidase inhibitors, and beta adrenergic blocking agents.  
 
8.1. Carcinogenesis, mutagenesis, impairment of fertility 
 A twenty month study in rats and an eighteen month study in mice 
at doses up to 75 times the maximum human dose revealed no evidence 
of drug-related carcinogenicity. Bacterial and in vivo mutagenicity tests 
were uniformly negative. Studies in rats of both sexes at doses up to 75 
times the human dose showed no effects on fertility. 
 
8.2. Pregnancy 
 Pregnancy Category C: Glipizide was found to be mildly fetotoxic in 
rat reproductive studies at all dose levels (5 – 50 mg/kg). 
 
8.3. Nonteratogenic effects 
 Prolonged severe hypoglycemia (4 to 10 days) has been reported in 
neonates born to mothers who were receiving a sulfonylurea drug at the 
time of delivery. 
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8.4. Geriatric use 
 Dose selection for an elderly patient should be cautious, usually 
starting at the low end of the dosing range, reflecting the greater frequency 
of decreased hepatic, renal or cardiac function, and of concomitant 
disease or other drug therapy. 
 
9. DOSAGE AND ADMINISTRATION 
9.1. Initial dose 
 The recommended starting dose is 5 mg, given before breakfast. 
Geriatric patients or those with liver disease may be started on 2.5 mg. 
Dosage adjustments should ordinarily be in increments of 2.5 to 5 mg, as 
determined by blood glucose response. The maximum recommended 
once daily dose is 15 mg. Doses above 15 mg should ordinarily be divided 
and given before meals of adequate caloric content. The maximum 
recommended total daily dose is 40 mg. 
 
9.2. Patients receiving insulin 
 As with other sulfonylurea-class hypoglycemics, many stable non-
insulin-dependent diabetic patients receiving insulin may be safely placed 
on glipizide when transferring patients from insulin to glipizide. 
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POLYMER PROFILE14 
 
ETHYLCELLULOSE 
Nonproprietary Names 
BP : Ethylcellulose 
PhEur : Ethylcellulosum 
USPNF : Ethylcellulose 
Synonyms 
 Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
Chemical Name and CAS registry number 
 Cellulose ethyl ether [9004-57-3] 
Functional category 
 Coating agent; suspending agent; tablet binder; thickening agent; 
viscosity – increasing agent. 
 
Applications in pharmaceutical formulation or technology 
 Ethylcellulose is widely used in oral and topical pharmaceutical 
formulations; see table 1. 
 The main use of ethylcellulose in oral formulations is as a 
hydrophobic coating agent for tablets and granules. Ethylcellulose 
coatings are used to modify the release to a drug to mask an unpleasant 
taste, or to improve the stability of a formulation; for example, where 
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granules are coated with ethylcellulose to inhibit oxidation. Modified – 
release tablet formulations may also be produced using ethylcellulose as a 
matrix former. 
 Ethylcellulose, dissolved in an organic solvent or solvent mixture, 
can be used on its own to produce water-insoluble films. Higher-viscosity 
ethylcellulose grades tend to produce stronger and more durable films. 
Ethylcellulose films may be modified to alter their solubility by the addition 
of hypromellose or a plasticizer. An aqueous polymer dispersion (or latex) 
of ethylcellulose such as Aquacoat ECD (FMC Biopolymer) or Surelease 
(Colorcon) may also be used to produce ethylcellulose films without the 
need for organic solvents. 
 Drug release through ethylcellulose-coated dosage forms can be 
controlled by diffusion through the film coating. This can be a slow process 
unless a large surface area (e.g. pellets or granules compared with 
tablets) is utilized. In those instances, aqueous ethylcellulose dispersions 
are generally used to coat granules or pellets. Ethylcellulose-coated beads 
and granules have also demonstrated the ability to absorb pressure and 
hence protect the coating from fracture during compression. 
 High-viscosity grades of ethylcellulose are used in drug 
microencapsulation. 
 Release of a drug from an ethylcellulose microcapsule is a function 
of the microcapsule wall thickness and surface area. 
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 In tablet formulations, ethylcellulose may additionally be employed 
as a binder; the ethylcellulose may additionally be wet-granulated with a 
solvent such as ethanol (95%). Ethylcellulose produces hard tablets with 
low friability, although they may demonstrate poor dissolution. 
 Ethylcellulose has also been used as an agent for delivering 
therapeutic agents from oral (e.g. dental) appliances. 
 In topical formulations, ethylcellulose is used as a thickening agent 
in creams, lotions, or gels, provided an appropriate solvent is used. 
 Ethylcellulose is additionally used in cosmetics and food products. 
 
Table 1: Uses of ethylcellulose 
Use Concentration (%) 
Microencapsulation 10.0 - 20.0 
Sustained – release tablet coating 3.0 - 20.0 
Tablet coating 1.0 - 3.0 
Tablet granulation 1.0 - 30.0 
 
Description 
 Ethylcellulose is a tasteless, free-flowing, white or light tan-colored 
powder. 
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Typical properties 
Density (bulk) : 0.4 g/cm3 
Glass transition temperature : 129-133°C 
Moisture content 
 Ethylcellulose absorbs very little water from humid air or during 
immersion, and that small amount evaporates readily. 
Solubility 
 Ethylcellulose is practically insoluble in glycerin, propylene glycol, 
and water. Ethylcellulose that contains less than 46.5% of ethoxyl groups 
is freely soluble in chloroform, methyl acetate, and tetrahydrofuran, and in 
mixtures of aromatic hydrocarbons with ethanol (95%). Ethylcellulose that 
contains not less than 46.5% of ethoxyl acetate, methanol, and toluene. 
Specific gravity : 1.12 - 1.15 g/cm3 
Viscosity 
 The viscosity of ethylcellulose is measured typically at 25° C using 
5% w/v ethylcellulose dissolved in a solvent blend of 80% toluene : 20% 
ethanol (w/w). Grades of ethylcellulose with various viscosities are 
commercially available. They may be used to produce 5% w/v solutions in 
organic solvent blends with viscosities nominally ranging from 7 to  
100 mPas (7-100 cp). Specific ethylcellulose grades, or blends of different 
grades, may be used to obtain solutions of a desired viscosity. Solutions of 
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higher viscosity tend to be composed of longer polymer chains and 
produce strong and durable films. 
 The viscosity of an ethylcellulose solution increase with an increase 
in ethylcellulose concentration; e.g., the viscosity of a 5% w/v solution of 
Ethocel Standard 4 Premium is 4 mPas (4 cP) and of a 25% w/v solution 
of the same ethylcellulose grade is 850 mPas (850 cP). Solutions with a 
lower viscosity may be obtained by incorporating a higher percentage  
(30 - 40%) of a low molecular-weight aliphatic alcohol such as ethanol, 
butanol, propan-2-ol, or n-butanol with toluene. The viscosity of such 
solutions depends almost entirely on the alcohol content and is 
independent of toluene. 
 In addition, non-pharmaceutical grades of ethylcellulose that differ 
in their ethoxyl content and degree of polymerization are available. 
Stability and storage conditions 
 Ethylcellulose is a stable, slightly hygroscopic material. It is 
chemically resistant to alkalies, both dilute and concentrated, and to salt 
solutions, although it is more sensitive to acidic materials than are 
cellulose esters. 
 Ethylcellulose is subject to oxidative degradation in the presence of 
sunlight or UV light at elevated temperatures. This may be prevented by 
the use of antioxidant and chemical additives that absorb light in the 230-
340 nm range. 
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 Ethylcellulose should be stored at a temperature not exceeding 
32°C (90°F) in a dry area away from all sources of heat. It should not be 
stored next to peroxides or other oxidizing agents. 
Incompatibilities 
 Incompatible with paraffin wax and microcrystalline wax. 
Safety 
 Ethylcellulose is widely used in oral and topical pharmaceutical 
formulations. It is also used in food products. Ethylcellulose is not 
metabolized following oral consumption and is therefore a noncalorific 
substance. Because ethycellulose is not metabolized it is not 
recommended for parenteral products; parenteral use may be harmful to 
the kidneys. 
 Ethylcellulose is generally regarded to be a health hazard; the WHO 
has not specified an acceptable daily intake. 
LD50 (rabbit, skin): >5 g/kg  
LD50 (rat, oral): >5 g/kg 
Handling precautions 
 It is important to prevent fine dust clouds of ethylcellulose from 
reaching potentially explosive levels in the air. Ethylcellulose is 
combustible. Ethylcellulose powder may be an irritant to the eyes and eye 
protection should be worn 
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MICROCRYSTALLINE CELLULOSE 
Nonproprietary Names 
BP : Microcrystalline cellulose 
JP : Microcrystalline cellulose 
PhEur : Cellulosum microcristallinum 
USPNF : Microcrystalline cellulose 
Synonyms 
 Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; 
Vivapur. 
Chemical Name and Cas Registry Number 
 Cellulose [9004-34-6] 
Empirical Formula and Molecular Weight 
 (C6H10O5)n ≈36 000. where n ≈ 220. 
Structural Formula 
 
Functional Category 
 Adsorbent; Suspending agent; Tablet and Capsule Diluent; Tablet 
Disintegrant. 
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Applications in Pharmaceutical Formulation 
 Microcrystalline cellulose is widely used in pharmaceuticals, 
primarily as a binder/diluent in oral tablet and capsule formulations where 
it is used in both wet-granulation and direct-compression processes. In 
addition to its use as a binder/diluent, microcrystalline cellulose also has 
some lubricant and disintegrant properties that make it useful in tableting. 
Microcrystalline cellulose is also used in cosmetics and food products. 
 
Table 2: Uses of microcrystalline cellulose 
Use Concentration (%) 
Adsorbent 20–90 
Antiadherent 5–20 
Capsule binder/diluent 20–90 
Tablet disintegrant 5–15 
Tablet binder/diluent 20–90 
 
Description 
 Microcrystalline cellulose is purified, partially depolymerized 
cellulose that occurs as a white, odorless, tasteless, crystalline powder 
composed of porous particles. It is commercially available in different 
particle sizes and moisture grades that have different properties and 
applications. 
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Typical Properties 
Solubility 
 Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents. 
Stability and storage conditions 
 Microcrystalline cellulose is a stable though hygroscopic material. 
The bulk material should be stored in a well-closed container in a cool, dry 
place. 
Incompatibilities 
 Microcrystalline cellulose is incompatible with strong oxidizing 
agents. 
Safety 
 Microcrystalline cellulose is not absorbed systemically following oral 
administration and thus has little toxic potential. Consumption of large 
quantities of cellulose may have a laxative effect, although this is unlikely 
to be a problem when cellulose is used as an excipient in pharmaceutical 
formulations. Deliberate abuse of formulations containing cellulose, either 
by inhalation or by injection, has resulted in the formation of cellulose 
granulomas. 
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HYDROXYETHYL CELLULOSE 
Nonproprietary Names 
BP : Hydroxyethylcellulose 
PhEur : Hydroxyethylcellulosum 
USPNF : Hydroxyethyl cellulose 
Synonyms 
 Alcoramnosan; Cellosize; cellulose hydroxyethyl ether; cellulose 
hydroxyethylate; ethylhydroxy cellulose; ethylose; HEC; HE cellulose; 2-
hydroxyethyl cellulose ether: hydroxyethyl ether cellulose; hydroxyethyl 
starch; hyetellose; Idroramnosan; Liporamnosan; Natrosal; oxycellulose; 
Tylose PHA. 
Chemical Name and CAS registry number 
 Cellulose, 2-hydroxyethyl ether [9004-62-0] 
Empirical formula & molecular weight 
 Ethylcellulose with complete substitution (DS=3) is C12H23O6 
(C12H22O5)n C12H23O5 where n can vary to provide a wide variety of 
molecular weights. Ethylcellulose, and ethyl ether of cellulose, is a long-
chain polymer of β-anhydroglucose units jointed together by acetal 
linkages. 
Functional category 
 Coating agent; flavoring fixative; tablet binder; tablet filler; viscosity 
– increasing agent. 
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Applications in pharmaceutical formulation or technology 
 Hydroxyethyl cellulose is a nonionic, water-soluble polymer widely 
used in pharmaceutical formulations. It is primarily used as a thickening 
agent in ophthalmic and topical formulations, although it is used as a 
binder and film-coating agent for tablets. It is present in lubricant 
preparations for dry eye, contact lens care, and dry mouth. The 
concentration of hydroxyethyl cellulose used in a formulation is dependent 
upon the solvent and the molecular weight of the grade. Hydroxyethyl 
cellulose is also widely used in cosmetics. 
Description 
 Hydroxyethyl cellulose occurs as a light tan or cream to white-
colored, odorless and tasteless, hygroscopic powder. 
Typical properties 
Density (bulk) 
 0.35 to 0.61 g/cm 3 for Cellosize, 0.60g/cm3 for Natrosol 
Moisture content 
 Hydroxyethyl cellulose is hygroscopic, the amount of water 
absorbed depends upon the initial moisture content and the relative 
humidity of surrounding air. Commercial grades of hydroxyethyl cellulose 
contains less than 5% w/w of water. 
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Solubility 
 Hydroxyethyl cellulose is soluble in either hot or cold water, forming 
clear, smooth, uniform solutions, practically insoluble in acetone, ethanol, 
ether, toluene, and most other organic solvents. In some polar organic 
solvents, such as the glycols hydroxyethyl cellulose either swells or is 
partially soluble. 
Specific gravity 
 1.38 - 1.40 g/cm3 for Cellosize. 
Stability and storage conditions 
 Hydroxyethyl cellulose powder is a stable, though hygroscopic, 
material. Aqueous solutions of hydroxyethyl cellulose are relative stable at 
pH 2 to 12 with the viscosity of solutions being largely unaffected. 
However, solutions are less stable below pH 5 owing to hydrolysis. At high 
pH, oxidation may occur. Increasing the temperature reduces the viscosity 
of aqueous hydroxyethyl cellulose solutions. However on cooling, the 
original viscosity is restored. Solutions may be subjected to freeze-
thawing, high-temperature storage, or boiling without precipitation or 
gelation occurring aqueous solutions of hydroxyethyl cellulose may also be 
sterilized by autoclaving. 
 Hydroxyethyl cellulose powder should be stored in a well-closed 
container in a cool, dry place. 
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Incompatibilities 
 Incompatible with Zein and with certain fluorescent dyes, optical 
brighteners and certain quaternary disinfectants. 
 
Handling precautions 
 Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Eye protection is recommended. 
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POLYETHYLENE GLYCOL 
Nonproprietary Names 
 BP : Macrogols 
 JP : Macrogol 400, Macrogol 1500, Macrogol 
4000, Macrogol 6000, Macrogol 20000 
 PhEur : Macrogola 
 USPNF : Polyethylene glycol 
Synonyms 
 Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; 
polyoxyethylene glycol. 
Chemical Name 
 α-Hydro-ω-hydroxypoly(oxy-1,2-ethanediyl) 
 
FUNCTIONAL CATEGORY 
 Ointment base; plasticizer; solvent; suppository base; tablet and 
capsule lubricant. 
 
APPLICATIONS IN PHARMACEUTICAL TECHNOLOGY 
 Polyethylene glycols (PEGs) are widely used in a variety of 
pharmaceutical formulations including parenteral, topical, ophthalmic, oral, 
and rectal preparations. It has been used in controlled-release systems. 
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 Polyethylene glycols are water-soluble and are easily removed from 
the skin by washing, making them useful as ointment bases. Aqueous 
polyethylene glycol solutions can be used either as suspending agents or 
to adjust the viscosity and consistency of other suspending vehicles. When 
used in conjunction with other emulsifiers, polyethylene glycols can act as 
stabilizers. 
 Liquid polyethylene glycols are used as water-miscible solvents for 
the contents of soft gelatin capsules. In concentrations up to approximately 
30% v/v, PEG 300 and PEG 400 have been used as the vehicle for 
parenteral dosage forms. Polyethylene glycols can also be used to 
enhance the aqueous solubility or dissolution characteristics of poorly 
soluble compounds by making solid dispersions with an appropriate 
polyethylene glycol. 
 In film coatings, solid grades of polyethylene glycol can be used 
alone for the film-coating of tablets. Solid grades are also widely used as 
plasticizers in conjunction with film-forming polymers. The presence of 
polyethylene glycols in film coats, especially of liquid grades, tends to 
increase their water permeability and may reduce protection against low 
pH in enteric-coating films. 
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Pharmacopeial Specifications 
Typical Properties 
Density : 1.11 to 1.14 g/cm3 at 25°C for liquid 
PEGs; 15 to 1.21 g/cm3 at 25°C for solid 
PEGs. 
Flash point : 250°C for PEG 6000 
Freezing point : 15 to 25°C for PEG 6000 
Melting point  : 55 to 63°C for PEG 6000 
Moisture content : Liquid polyethylene glycols are very 
hygroscopic, hygroscopicity decreases 
with increasing molecular weight. Solid 
grades. 
Solubility 
 Soluble in water, liquid PEG are soluble in acetone, alcohols, 
benzene, glycerin, and glycols. Solid polyethylene glycols are soluble in 
acetone, dichloromethane, ethanol (95%), and methanol; they are slightly 
soluble in aliphatic hydrocarbons and ether, but insoluble in fats, fixed oils, 
and mineral oil. 
Surface tension 
 Approximately 44 mN/m (44 dynes/cm) for liquid polyethylene 
glycols; approximately 55 mN/m (55 dynes/cm) for 10% w/v aqueous 
solution of solid polyethylene glycol. 
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Stability and storage conditions 
 Polyethylene glycols are chemically stable in air and in solution, 
although grades with a molecular weight less than 2000 are hygroscopic. 
Polyethylene glycols do not support microbial growth, and they do not 
become rancid. 
 Polyethylene glycols should be stored in well-closed containers in a 
cool, dry place. Stainless steel, aluminum, glass, or lined steel containers 
are preferred for the storage of liquid grades. 
 
Incompatibilities 
 All grades can exhibit some oxidizing activity owing to the presence 
of peroxide impurities and secondary products formed by autoxidation. 
Liquid and solid polyethylene glycol grades may be incompatible with 
some coloring agents.The antibacterial activity of certain antibiotics is 
reduced in polyethylene glycol bases. The preservative efficacy of the 
parabens may also be impaired owing to binding with polyethylene glycols. 
 
Handling precautions 
 Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Eye protection is recommended. 
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Regulatory status 
 Included in the FDA Inactive Ingredients Guide (dental 
preparations; IM and IV injections; ophthalmic preparations; oral capsules, 
solutions, syrups, and tablets; rectal, topical, and vaginal preparations). 
Included in nonparenteral medicines licensed in the UK. Included in the 
Canadian List of Acceptable Non-medicinal Ingredients. 
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LITERATURE REVIEW 
1. Aruna, A. and Nancy, K (2000)15 developed a UV 
spectrophotometric method based on the measurement of 
absorbance at 276 nm in pH 7.4 phosphate buffer for glipizide, the 
method obeyed Beer's law in the concentration range 5 - 30 µg/ml. 
2. Kung-Hsu Lin et al., (2001)16 studied the influence of compression 
force to inner core tablet (or) to outer coating layer of the 
compression-coated tablet on the function of the time controlled 
disintegration. 
3. Anjali M. Agarwal, Steven H. Neau (2003)17 evaluated the wet 
granulated fine particle ethylcellulose matrix tablets. 
4. Shan-Yang Lin and Mei-janeli (2004)18 formulated an oral press-
coated tablet by direct compression to achieve the time controlled 
disintegration (or) rupturing function with a distinct predetermined 
lag time. 
5. P. Venkatesh et al., (2005)19 developed a method for the separation 
and simultaneous estimation of six anti-diabetic drugs -
glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and 
rosiglitazone in pharmaceutical formulations. The assay developed 
for formulation analysis was found to be precise and accurate. The 
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calibration curves ranged from 0.1 to 100 µg/ml. The drugs were 
monitored at a wavelength of 260 nm. 
6. N. Vishal Gupta et al., (2007)20 prepared and characterized gelatin-
poly (methacrylic acid) interpenetrating polymeric network 
hydrogels as a pH-sensitive delivery system for glipizide, drug 
release from the IPN hydrogels was studied in 900 ml of dissolution 
medium (2 h in 0.1 N hydrochloric acid solution and 10 h in pH 7.4 
phosphate buffer) at 276 nm. 
7. Sundaramoorthy K., Kavimani S (2008)21 formulated and evaluated 
an extended release dosage form of metformin hydrochloride using 
combined hydrophobic and hydrophilic matrix. Extended release 
matrix tablets of metformin hydrochloride were formulated using 
ethylcellulose and hydroxypropylmethylcellulose in varying ratios by 
direct compression method. 
8. Linsy, Lin K.H. et al.,22 investigated the influence of release of drug 
from different weight ratios of coarse / fine particles of EC powder in 
outer shell of formulation. 
9. Linsy, Lin K.H., Li M.J.,23 designed a directly compressed time-
controlled disintegration tablet using different grades of micronized 
ethylcellulose. 
10. Watanable Y., Mukai B., Utoguchi N. et al.,24 prepared and 
evaluated the press coated aminophylline tablet using crystalline 
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cellulose and polyethylene glycol in the outer shell for timed-release 
dosage forms. 
11. Shan-Yang Ling et al.,25 studied the influence of excipients and 
osmotic agents in the inner core on the time-controlled 
disintegration of compression-coated ethyl cellulose tablets. 
12. Jomjai Peerpattana et al.,26 formulated a colon drug delivery system 
using dry coated time controlled disintegration wax matrix tablets. 
The effect of pH of the dissolution medium on drug release was 
also investigated. 
13. Ian R. Wilding27 studied the site specific drug delivery in 
gastrointestinal tract to maximize therapeutic response and to 
reduce side effects. 
14. Vyas S.P., Shihorkar V.,28 used endogenous carriers and ligands in 
non-immunogenic site-specific drug delivery. To explore potential 
and possibilities of cell biologically related bioevents in the 
development of specific preprogrammed and target oriented 
systems. 
15. Hyo-Kyung Han et al.,8 developed targeted prodrug design 
representing a new strategy for directed and efficient drug delivery. 
16. Clausen A.E. et al.,29 used direct compressible polymethacrylic 
acid-starch compositions for site-specific drug delivery. 
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17. Biswanthsa, Jayantha Chowdhury, et al.,30 studied the rate of 
release of sodium benzoate, salbutamol sulphate and caffeine from 
ethylcellulose microparticles. 
18. S.K. Gupta, Jai Prakash, et al.,31 studied about role of non-steroidal 
anti-inflammatory drugs in the management of cancer. 
19. K.S. Aithal, et al.,32 used ethylcellulose and hydroxylpropyl 
methylcellulose as polymer in controlled fluoride release tablets. 
20. Nagesh Badwe, et al.,33 gave a practical aspect of direct 
compression. 
21. G.W. Skinner, et al.,34 evaluate a new grade of ethyl cellulose, 
Aqualon T10 Pharma ethyl cellulose (T10 EC), for compression 
coating of time-controlled dosage forms. This new grade has high 
ethoxy content and low viscosity, yielding optimized compatibility 
and good powder flow. 
22. Madhusudan Hariharan et al., 35 developed a novel compression 
coated tablet dosage form which describes the dosage form not 
requires the separate formation of the core tablet because the core 
material and outer compression coating material are formed into a 
tablet in the same tablet press and on a single turret. 
23. Wardrop J., Jaber A.B., et al.,36 formulated the novel multiple layer 
compression coated chewable tablets and studied the effect of 
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humidity, stability compared to marketed chewable tablets as a 
reference. 
24. T. Durig, W.W. Harcum, et al.,37 characterized the unique physical-
chemical and compaction properties of high ethoxyl, low viscosity 
ethylcellulose in relation to other grades of ethyl cellulose with 
varying ethoxyl content and molecular weight. 
25. Fukui et al.,38 studied on applicability of press-coated tablets, 
containing diltiazem hydrochloride (DIL) in the core tablet and 
coated with hydroxylpropylcellulose (HPC) as the outer shell, were 
examined for applicability as timed-release tablets with a 
predetermined lag time and subsequent rapid drug release phase. 
26. Fukui, et al.,39 formulated enteric coated timed-release press coated 
tablets and evaluation of their function by in vitro and in vivo tests 
for colon targeting. 
27. Martti Marvola, et al.,40 studied the development and 
biopharmaceutical evaluation of press-coated tablets with the 
intention of administering formulation in the evening at 22:00, which 
provides treatment for diseases in which symptoms are 
experienced in the early morning hours i.e. 
chronopharmacotherapy. 
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28. Melendez M., Ghaly E.S.,41 studied the mechanism of release of 
drug from hydrophilic polymer and to quantify the amount of drug 
released. 
29. Rahmounium, Lenaerts et al.,42 studied the characterization of 
hydroxylpropylmethylcellulose in controlled release tablets. 
30. Hamid A. Merchant, Harris M. Shoaib, Jaweria Tazeen43, once-daily 
tablet formulation and in vitro release evaluation of cefpodoxime 
using hydroxypropyl methylcellulose: a technical note. 
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MATERIALS AND EQUIPMENTS 
 
Table 3: Materials used 
Material Source 
Glipizide Franco-Indian Pharmaceuticals, 
Chennai. 
Microcrystalline cellulose SD Fine Chemicals, Mumbai. 
Ethylcellulose SD Fine Chemicals, Mumbai. 
Hydroxyethyl cellulose Himedia Laboratories, Mumbai. 
Polyethylene glycol 6000 Himedia Laboratories, Mumbai. 
Methanol SD Fine Chemicals, Mumbai. 
 
Table 4: Equipments used 
Equipment Model / Company 
Tablet punching machine Rimek mini press 
UV-visible spectrophotometer Jasco V-530 
FT-IR spectrophotometer Jasco-FT-IR 8201 PC 
Digital balance Denver instruments 
Dissolution test apparatus Lab India disso 2000 
Pfizer Hardness tester Scientific Engineering Corporation 
Friability tester Remi equipments 
 
Chapter 7  Analytical Methods 
 77
ANALYTICAL METHODS 
 
METHODS FOR ESTIMATION OF GLIPIZIDE 
1) HPLC determination of glipizide in human plasma and urine has 
been reported. The response was linear (0-1000 ng/ml) and the 
detection limit was 5-10 ng/ml in plasma or urine. A Spherisorb 
ODS reversed-phase column was used. Quantitation was achieved 
by monitoring the ultraviolet absorbance at 275 nm44. 
2) Simultaneous determination of glipizide with other antidiabetic 
drugs in plasma and urine were reported by liquid chromatography-
tandem mass spectrometry45. 
 
1. THE METHODOLOGY USED IN THE PRESENT STUDY IS  
UV SPECTROPHOTOMETRY46,47  
1.1. Potassium dihydrogen phosphate, 0.2 M solution 
 Take accurately weighed 27.318 gm of Potassium dihydrogen 
phosphate and dissolved in 1000 ml of distilled water, this will give 0.2 M 
KH2PO4 
1.2. Sodium hydroxide 0.2 N solution 
 Take accurately weighed 8 gm of sodium hydroxide and dissolved 
in 1000 ml of distilled water, this will give 0.2 N NaOH solution. 
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1.3. Preparation of pH 7.4 phosphate buffer  
 Place 50 ml of the potassium dihydrogen phosphate solution in a 
200 ml standard volumetric flask and add 39.1 ml of sodium hydroxide 
solution to this flask and make up the volume with distilled water. 
1.4 Preparation of 0.2 M potassium chloride 
 Dissolve 14.911 gm of potassium chloride in 1000 ml of distilled 
water. This will give 0.2 M potassium chloride. 
1.5 Preparation of 0.2 M hydrochloric acid 
 Place 7.292 gm (17.8 ml) of hydrochloric acid in 1000 ml of distilled 
water, this will give 0.2 M HCl acid 
1.6 Preparation of pH 1.2 HCl acid buffer 
 Place 50 ml of the 0.2 M potassium chloride in a 200 ml volumetric 
flask, then add 85 ml of 0.2 M hydrochloric acid and then add distilled 
water to make up the volume. 
 
2. PROCEDURE FOR STANDARD GRAPHS PREPARATION 
2.1. Standard graphs preparation in phosphate buffer pH 7.420 
 Accurately weigh 100 mg of glipizide  and transfer to a 100 ml 
volumetric flask and add minimum quantity of methanol to solubilise the 
drug, and then add phosphate buffer pH 7.4 to make up the volume up to 
100 ml, this gives the stock solution I (1000 µg/ml). 
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 From stock solution I, pipette out 10 ml and make up the volume to 
100 ml with phosphate buffer pH 7.4, this gives the stock solution II  
(100 µg/ml). 
 From the stock solution II, pipette out 0.5, 1.0, 1.5, 2.0, and 2.5 ml 
into 5 separate 10 ml volumetric flasks respectively, then make up the 
volume up to the mark to give 5, 10, 15, 20 and 25 µg/ml concentration 
solutions and the phosphate buffer pH 7.4 was taken as blank. 
 The absorbance was measured at 276 nm and the graph was 
plotted against concentration (µg/ml) vs. absorbance. 
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Table 5: Standard graph of glipizide in phosphate buffer pH 7.4 
Sl. No. Concentration (µg/ml) Absorbance at 276 nm 
1 0 0.000 
2 5 0.115 
3 10 0.228 
4 15 0.332 
5 20 0.443 
6 25 0.556 
 
Fig. 1: Standard graph of glipizide with phosphate buffer pH 7.4 
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2.2. Standard graphs preparation in hydrochloric acid buffer pH 1.2 
 Accurately weigh 100 mg of glipizide  and transfer to a 100 ml 
volumetric flask and add minimum quantity of methanol to solubilise the 
drug, and then add phosphate buffer pH 1.2 to make up the volume up to 
100 ml, this gives the stock solution I (1000 µg/ml). 
 From stock solution I, pipette out 10 ml and make up the volume to 
100 ml with phosphate buffer pH 1.2, this gives the stock solution II  
(100 µg/ml). 
 From the stock solution II, pipette out 0.5, 1.0, 1.5, 2.0, and 2.5 ml 
into 5 separate 10 ml volumetric flasks respectively, then make up the 
volume up to the mark to give 5, 10, 15, 20 and 25 µg/ml concentration 
solutions and the phosphate buffer pH 1.2 was taken as blank. 
 The absorbance was measured at 260 nm and the graph was 
plotted against concentration (µg/ml) vs. absorbance.  
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Table 6: Standard graph of glipizide in phosphate buffer pH 1.2 
Sl. No. Concentration (µg/ml) Absorbance at 260 nm 
1 0 0.000 
2 5 0.082 
3 10 0.165 
4 15 0.247 
5 20 0.329 
6 25 0.402 
 
Fig. 2: Standard graph of glipizide in phosphate buffer pH 1.2 
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Standard graphs preparation in methanol 
 Accurately weigh 100 mg of glipizide  and transfer to a 100 ml 
volumetric flask and add methanol to solubilise the drug, and make up the 
volume up to 100ml, this gives the stock solution (1000 µg/ml). 
 From stock solution I, pipette out 10 ml and make up the volume to 
100 ml with methanol, this gives the stock solution II (100 µg/ml). 
 From the stock solution II, pipette out 0.5, 1.0, 1.5, 2.0, and 2.5 ml 
into 5 separate 10 ml volumetric flasks respectively, then make up the 
volume up to the mark to give 5, 10, 15, 20 and 25 µg/ml concentration 
solutions and the methanol was taken as blank. 
 The absorbance was measured at 276 nm and the graph was 
plotted against concentration (µg/ml) vs. absorbance. 
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Table 7: Standard graph of glipizide in methanol 
Sl. No. Concentration (µg/ml) Absorbance at 276 nm 
1 0 0.0000 
2 5 0.1190 
3 10 0.2420 
4 15 0.3610 
5 20 0.4810 
6 25 0.6040 
 
Fig. 3: Standard graph of glipizide in methanol 
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FORMULATION OF TIME CONTROLLED 
RELEASE TABLETS CONTAINING GLIPIZIDE 
 
 Glipizide is a second generation of sulphonyl urea, used for 
lowering blood glucose. The different formulations of glipizide time 
controlled tablets were formulated by direct compression method using a 
combination of hydrophobic polymer ethylcellulose and hydrophilic 
polymers polyethylene glycol 6000 and hydroxyethylcellulose in outer 
coating layer. 
 The formulation of time controlled release tablet by using press-
coating technique with ethylcellulose as hydrophobic polymer and 
hydrophilic polymers polyethylene glycol (PEG) and hydroxyethylcellulose 
(HEC). 
METHOD 
 The press-coated tablets were formulated by using a tablet press 
under constant pressure. An inner core of the drug tablet (glipizide 10 mg) 
was previously direct compacted with 40 mg of MCC. Different weight 
ratios of (w/w) of EC/excipient mixture were formulated and each 
EC/excipient mixture (50 mg) was first filled into a die and the inner core 
tablet was then manually placed in the center of the EC/excipient powder 
bed. The remaining EC/ excipient powder (50 mg) was then poured on to 
the inner core tablet and compressed to prepare the compression-coated 
tablet. 
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Table 8: Formula for glipizide time controlled release tablets  
S. 
No. 
Ingredients 
mg/tab F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 
1. Glipizide 10 10 10 10 10 10 10 10 10 10 10 10 10 10 
2. Microcrystalline cellulose 40 40 40 40 40 40 40 40 40 40 40 40 40 40 
3. Ethyl cellulose 100 80 60 50 40 20 0 100 80 60 50 40 20 0 
4. Polyethylene glycol 6000 0 20 40 50 60 80 100 - - - - - - - 
5. Hydroxy ethylcellulose - - - - - - - 0 20 40 50 60 80 100 
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Table 9: Tablet formulation  containing hydrophobic polymer 
ethylcellulose and hydrophilic polymer PEG as excipient in outer 
coating layer 
S. NO. TYPE EC PEG IN PERCENTAGE 
1 F1 100mg 0 mg (100, 0) 
2 F2 80 mg 20 mg (80, 20) 
3 F3 60 mg 40 mg (60, 40) 
4 F4 50 mg 50 mg (50, 50) 
5 F5 40 mg 60 mg (40, 60) 
6 F6 20 mg 80 mg (20, 80) 
7 F7 0 mg 100 mg (0, 100) 
 
Table 10: Tablet formulation  containing hydrophobic polymer 
ethylcellulose and hydrophilic polymer HEC as excipient in outer 
coating layer 
S. NO TYPE EC HEC IN PERCENTAGE 
1 F8 100mg 0 mg (100, 0) 
2 F9 80 mg 20 mg (80, 20) 
3 F10 60 mg 40 mg (60, 40) 
4 F11 50 mg 50 mg (50, 50) 
5 F12 40 mg 60 mg (40, 60) 
6 F13 20 mg 80 mg (20, 80) 
7 F14 0 mg 100 mg (0, 100) 
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EVALUATION OF TABLETS 
 
 The formulated tablets were subjected for the following quality 
control tests: 
• Weight variation 
• Friability 
• Hardness 
• Drug content uniformity 
• Compatibility studies 
• In vitro dissolution studies 
 
Weight variation test 
 Twenty tablets were taken weighed individually as per BP. They 
were evaluated for the weight variations. The weight variation allowed as 
per BP limit is 7.5%. The weights of tablet were within the BP limits. The 
results were shown in table no. 12, 13. 
Table 11: Percentage deviation of tablets as per weight range 
Pharmaceutical form Average mass % Deviation 
≤ 80 mg ± 10 
> 80 mg - 250 mg ± 7.5 
 
Tablets 
≥ 250 mg ± 5 
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Table 12: Weight variation of glipizide tablets containing EC/PEG 
formulation in outer layer 
S. 
No. 
Formulation 
code 
Weight range of 
20 Tablets 
Average 
weight 
Limit range 
(±7.5%) 
1 F1 144-156 152 140.6-163.4 
2 F2 147-158 148 136.9-159.1 
3 F3 145-157 146 135.1-156.9 
4 F4 141-153 155 143.4-166.6 
5 F5 146-154 151 139.7-162.3 
6 F6 139-156 149 137.9-160.1 
7 F7 143-159 154 142.5-165.5 
 
Table 13: Weight variation of glipizide tablets containing EC/ HEC 
formulation in outer layer 
S. 
No. 
Formulation 
code 
Weight range of 
20 Tablets 
Average 
weight 
Limit range 
(±7.5%) 
1 F8 142-159 153 141.6-164.4 
2 F9 146-153 149 137.9-160.1 
3 F10 143-159 155 143.4-166.6 
4 F11 140-154 147 136.0-158.0 
5 F12 144-158 151 139.7-162.3 
6 F13 141-155 145 134.2-155.8 
7 F14 147-159 154 142.5-165.5 
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Friability test 
 Friability test was performed on the formulated tablets. The weight 
of the tablets after undergoing 100 revolutions was found to be within the 
limits 0.5 to 1.0%. The results were shown in table 14, 15. 
Hardness 
 Pfizer hardness tester was used for measuring the hardness of 
formulated glipizide CR tablets. Five tablets were taken randomly and 
subjected to test. The hardness was found to be 4-6 kg/cm2. The results 
were shown in table 14, 15 
Table 14: Hardness, friability of glipizide press coated tablets for 
EC/PEG formulation 
S. No. Formulation 
code 
Hardness 
(kg/cm2) 
Friability (%) 
1 F1 4.8 0.56 
2 F2 5.2 0.51 
3 F3 5.4 0.54 
4 F4 5.0 0.61 
5 F5 4.9 0.55 
6 F6 4.7 0.52 
7 F7 4.7 0.54 
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Table 15: Hardness, friability of glipizide press coated tablets for 
EC/HEC formulation 
S No. Formulation 
code 
Hardness 
(kg/cm2) 
Friability (%) 
1 F8 5.6 0.48 
2 F9 5.3 0.63 
3 F10 5.4 0.57 
4 F11 5.1 0.52 
5 F12 4.9 0.51 
6 F13 5.1 0.49 
7 F14 4.6 0.46 
 
Drug content uniformity 
 The prepared tablets containing glipizide was tested for drug 
content uniformity. Tablets were dissolved in 100 ml of methanol in 100 ml 
volumetric flask which was previously clean and dry. This solution after 
suitable dilution was measured for absorbance at 276 nm in a Jasco V530 
UV visible spectrophotometer. The results were shown in table 16, 17. 
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Table 16: Drug content uniformity for glipizide tablets containing 
EC/PEG formulation in outer layer 
Amount of Glipizide Tablet 
S. No. Formulation code 
Amount in milligram Amount in % 
1 F1 9.98 99.8 
2 F2 10.34 103.4 
3 F3 10.26 102.6 
4 F4 9.93 99.39 
5 F5 10.16 101.6 
6 F6 10.41 104.1 
7 F7 10.07 100.7 
 
Table 17: Drug content uniformity for glipizide tablets containing 
EC/HEC formulation in outer layer 
Amount of Glipizide per Tablet 
S. No. Formulation code 
Amount in milligram Amount in % 
1 F8 10.38 103.8 
2 F9 10.14 101.4 
3 F10 10.41 104.1 
4 F11 9.93 99.3 
5 F12 10.16 101.6 
6 F13 10.28 102.8 
7 F14 10.21 102.1 
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COMPATIBILITY STUDIES 
 Before formulation of a drug substance into a dosage form, it is 
essential that it should be chemically and physically characterized. 
Compatibility studies give the information needed to define the nature of 
the drug substances and provide a frame work for the drug combination 
with pharmaceutical excipients in the fabrication of a dosage form. 
 One of the requirements for the selection of suitable excipients or 
carrier for pharmaceutical formulation is its compatibility. Therefore in the 
present work, a study was carried out by using infrared spectrophotometer 
to find out if there is any possible chemical interaction between glipizide 
and the excipients. 
 Weighed amount of drug (3 mg) was mixed with 100 mg of 
potassium bromide (dried at 40-50°C). The mixture was taken and 
compressed under 10-ton pressure in a hydraulic press to form a 
transparent pellet. The pellet was scanned from 4000-400cm-1 in IR 
spectrophotometer. 
 
IR spectral analysis 
 Using Jasco-FT-IR 8201 PC spectrometer the compatibility studies 
between drug and excipients were carried out. The principal peaks were 
observed in the range of 1600-1000 cm-1. 
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 There was no appearance or disappearance of any characteristic 
peak, which confirms the absence of chemical interaction between drug 
and carrier. The IR spectra of glipizide time controlled release tablets were 
shown in fig. 4 - 10. 
 
Fig. 4: IR spectra of glipizide 
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Fig. 5: IR spectra of microcrystalline cellulose 
 
Fig. 6: IR spectra of ethylcellulose 
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Fig. 7: IR spectra of polyethylene glycol 6000 
 
Fig. 8: IR spectra of hydroxyethyl cellulose 
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Fig. 9: IR spectra of formulation F4 (EC/PEG) 
 
Fig. 10: IR spectra of formulation F4 (EC/HEC) 
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IN VITRO DISSOLUTION STUDIES18,20,21 
 The release of glipizide from the press-coated tablets was studied 
in 900 ml of dissolution medium using a USP dissolution paddle assembly 
(Lab India Disso 2000) instrument at 50 rpm and 37±0.5°C. The 
dissolution medium used were 
I. Hydrochloric acid buffer (1.2 pH) 
II. Phosphate buffer (pH 7.4) 
 Samples of dissolution medium were withdrawn at suitable time 
interval and was then determined spectrophotometrically at 276 nm for pH 
7.4 and at 260 nm for pH 1.2. Cumulative percentage drug release was 
calculated using an equation obtained from the standard curve. 
 Percentage release of glipizide from press-coated tablets 
formulated by using different weight ratios of ethylcellulose with 
polyethylene glycol 6000 (PEG 6000) in the formulation of outer shell. The 
weight ratios of EC/PEG mixtures are 100%/0%; 80%/20%; 60%/40%; 
50%/50%; 40%/60%; 20%/80%; 0%/100%. 
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Table 18: Dissolution profile of glipizide from formulation (F1) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 16 - 0 
17 - 13 
18 - 28.2 
19 - 37.6 
20 - 42.1 
21 - 49.9 
22 - 59.7 
 
Table 19: Dissolution profile of glipizide from formulation (F2) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 14 - 0 
15 - 13.9 
16 - 29.86 
17 - 40.4 
18 - 45.8 
19 - 54.8 
20 - 62.5 
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Table 20: Dissolution profile of glipizide from formulation (F3) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 12 - 0 
13 - 15.1 
14 - 32.3 
15 - 40.4 
16 - 50.31 
17 - 59.7 
18 - 69.1 
 
Table 21: Dissolution profile of glipizide from formulation (F4) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 10 - 0 
11 - 16.3 
12 - 35.5 
13 - 44.1 
14 - 57.6 
15 - 70.3 
16 - 78.1 
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Table 22: Dissolution profile of glipizide from formulation (F5) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 8 - 0 
9 - 29.4 
10 - 40.3 
11 - 52.7 
12 - 63.8 
13 - 76.9 
14 - 80.9 
 
Table 23: Dissolution profile of glipizide from formulation (F6) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 6 - 0 
7 - 34.3 
8 - 44.5 
9 - 59.3 
10 - 72.8 
11 - 80.1 
12 - 86.7 
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Table 24: Dissolution profile of glipizide from formulation (F7) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 3 0 0 
4 16.2 24.1 
5 - 38.0 
6 - 52.3 
7 - 71.5 
8 - 84.2 
9 - 89.9 
10 - 95.3 
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Fig. 11: Percentage of drug release of glipizide (pH 1.2) which contain 
EC/PEG in outer coating layer 
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Fig. 12: Percentage of drug release of glipizide (pH 7.4) which contain 
EC/PEG in outer coating layer 
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 Percentage release of Glipizide from press-coated tablets 
formulated by using different weight ratios of ethylcellulose with 
hydroxyethyl cellulose (HEC) in the formulation of outer shell. The weight 
ratios of EC/HEC mixtures are 100%/0%; 80%/20%; 60%/40%; 50%/50%; 
40%/60%; 20%/80%; 0%/100%. 
 
Table 25: Dissolution profile of glipizide from formulation (F8) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 17 - 0 
18 - 15.9 
19 - 31.0 
20 - 39.2 
21 - 47.7 
22 - 56.4 
23 - 62.1 
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Table 26: Dissolution profile of glipizide from formulation (F9) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 15 - 0 
16 - 16.2 
17 - 35.9 
18 - 44.9 
19 - 51.9 
20 - 61.7 
21 - 67.8 
 
Table 27: Dissolution profile of glipizide from formulation (F10) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 12 - 0 
13 - 28.1 
14 - 38.7 
15 - 52.2 
16 - 61.7 
17 - 72.3 
18 - 81.8 
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Table 28: Dissolution profile of glipizide from formulation (F11) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 10 - 0 
11 - 31.8 
12 - 40.4 
13 - 58.0 
14 - 61.7 
15 - 73.6 
16 - 86.2 
 
Table 29: Dissolution profile of glipizide from formulation (F12) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 7 - 0 
8 - 37.6 
9 - 48.2 
10 - 61.2 
11 - 67.0 
12 - 82.9 
13 - 90.3 
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Table 30: Dissolution profile of glipizide from formulation (F13) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 5 - 0 
6 - 38.4 
7 - 51.1 
8 - 61.7 
9 - 73.9 
10 - 86.6 
11 - 94.4 
 
Table 31: Dissolution profile of glipizide from formulation (F14) 
Percentage Released 
Hours 
pH 1.2 pH 7.4 
0 - 3 0 0 
4 16.0 40.0 
5 - 54.3 
6 - 76.0 
7 - 88.7 
8 - 89.9 
9 - 98.1 
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Fig. 13: Percentage of drug release of glipizide (pH 1.2) which contain 
EC/HEC in outer coating layer 
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Fig. 14: Percentage of drug release of glipizide (pH 7.4) which contain 
EC/HEC in outer coating layer 
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DISSOLUTION KINETICS 
 
 Three categories of dissolution test specifications for drug products 
are described in the guidance. Single point specifications are 
recommended as a routine quality control test for highly soluble and 
rapidly dissolving drug products. This comparison method can be 
employed in evaluating scale-up and post-approval changes such as 
manufacturing site changes, component and composition changes, 
equipment changes and process changes. Two-point specifications are 
suggested for characterizing the quality of drug product and for accepting 
product sameness under SUPAC-related changes. In the presence of 
certain minor changes the single point dissolution test may be adequate to 
ensure unchanged product quality and performance. For more major 
changes a dissolution profile comparison performed under identical 
conditions for the product before and after the changes is recommended. 
Dissolution profiles may be considered similar by virtue of overall profile 
similarity and similarity at every dissolution sample time point. 
 Method used to compare dissolution data is: 
• Model Dependent Methods (zero order, first order, Higuchi’s, 
Korsmeyer’s) 
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Drug Release Kinetics43 
 To study the release kinetics, data obtained from in vitro drug 
release studies were plotted in various kinetic models: zero order 
(Equation 1) as cumulative amount of drug released vs. time, first order 
(Equation 2) as log cumulative percentage of drug remaining vs. time, and 
Higuchi’s model (Equation 3) as cumulative percentage of drug released 
vs. square root of time. 
 C = tK0  (Equation 1) 
where K0 is the zero-order rate constant expressed in units of 
concentration/time and t is the time in hours. 
 A graph of concentration vs. time would yield a straight line with a 
slope equal to K0 and intercept the origin of the axes. 
 30320 ./ktCloglogc −=  (Equation 2) 
where C0 is the initial concentration of drug, 
 k is the first order constant, and t is the time. 
 Q = 2
1
Kt  (Equation 3) 
where K is the constant reflecting the design variables of the system 
 t is the time in hours. 
 Hence, drug release rate is proportional to the reciprocal of the 
square root of time. 
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 Drug release were plotted in Korsmeyer et al., equation (Equation 
4) as log cumulative percentage of drug released vs. log time, and the 
exponent n was calculated through the slope of the straight line. 
 nt KtMM =∞  (Equation 4) 
where Mt/M∞ is the fractional solute release, t is the release time, 
 K is a kinetic constant 
Table 32: Drug Release Kinetics for glipizide time controlled  
release tablets 
Formulation Zero Order R2 
First 
Order R2 
Higuchi's 
Plot R2 
Korsmeyer's 
Plot R2 
F1 0.774 0.774 0.683 0.578 
F2 0.740 0.756 0.662 0.540 
F3 0.699 0.725 0.626 0.507 
F4 0.634 0.639 0.564 0.468 
F5 0.782 0.774 0.736 0.652 
F6 0.846 0.897 0.838 0.745 
F7 0.962 0.936 0.985 0.923 
F8 0.652 0.635 0.561 0.559 
F9 0.779 0.718 0.708 0.769 
F10 0.726 0.674 0.647 0.599 
F11 0.745 0.705 0.675 0.617 
F12 0.810 0.828 0.781 0.673 
F13 0.845 0.897 0.860 0.722 
F14 0.906 0.921 0.952 0.825 
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RESULTS AND DISCUSSION 
 Based on the concept of chronotherapy (or) chronopharmacology, 
recent pharmaceutical investigations have focused on developing a site-or 
time controlled drug delivery system for the treatment of various diseases. 
 Site and/or time controlled release preparation is preferred when 
higher regional drug levels can be obtained as compared to those of other 
routes of administration. A resultant benefit is observed (or) eliminated 
side effects related to high systemic drug levels. These preparations 
enable us to predict and reproduce the drug absorption at the 
predetermined time and/or site. The press coating technique is one of the 
novel methods and has been applied for many drugs to develop the site –
and /or time-controlled release preparation. 
 
COMPATIBILITY STUDIES 
 The compatibility studies between the drugs and polymer were 
evaluated by using IR matching approach. 
 
FT-IR SPECTRAL ANALYSIS 
 In IR studies, there was no appearance or disappearance of 
characteristics peaks in pure drug and drug excipient mixture. In glipizide 
IR spectrum, principal peaks were noticed at following wave numbers 
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1587, 1526, 1346, 1158, 1032 cm-1 (KBr pellet). The IR spectra obtained 
were given in fig. 4 to 10. This method confirms the absence of any 
chemical interaction between drug and polymer. 
 
EVALUATION OF GLIPIZIDE TIME CONTROLLED RELEASE TABLETS 
 All the formulated glipizide time controlled release tablets (F1-F14) 
have fulfilled official requirements for weight variation and drug content 
uniformity (table 12, 13 and 16, 17), hardness of the tablets in all the 
batches were found to be in the range of 4.3 to 5.6 kg/cm2 (table 14, 15) 
and was satisfactory. The percentage weight loss in the friability test was 
found to be less than 1% in all formulations (table 14, 15) were found to be 
good quality fulfilling the tablets. 
 
DISSOLUTION STUDIES 
Effect of hydrophilic excipients to modulate the time lag of drug 
release behavior 
 The dissolution profile of all the formulated glipizide time controlled 
release tablets were reported in table 18 - 31. 
 
 The press-coating technique is one of the novel methods and has 
been applied to design a time-controlled disintegrating press-coated tablet 
by using ethylcellulose as an outer coating shell. In this study we try to 
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modulate the time lag of drug released from this time-controlled 
disintegrating press-coated tablet by adding the hydrophilic polymer as 
excipient in the outer coated layer. It is well known that the additions of 
MCC in the inner core can improve the flow and bond prosperities of the 
excipients during direct compression. MCC acts as an disintegrating 
agent. PEG 6000 was mixed with EC to alter the time lag and time 
controlled disintegration of tablet and figure 11,12 shows the dissolution 
profiles of press–coated tablets prepared by using different weight ratios of 
EC and PEG 6000 in the outer shell. The profiles clearly indicate that the 
glipizide released from the press-coated tablet exhibited a unique release 
profile depending on the amount of PEG 6000 and EC used. The profile 
exhibited an induction period (time lag) followed by a rapid drug release 
phase. The drug was rapidly and completely released from the press-
coated tablet after a lag period of several hours, depending upon the 
weight ratios of EC and PEG 6000. The formulation of tablet prepared by 
press-coating technique using EC as hydrophobic polymer without 
hydrophilic polymer exhibited a longer lag period of hours followed by 
faster drug release. 
 
 The sudden splitting of the outer shell of press-coated tablets into 
two halves after the lag period is a key factor to achieve the time-
controlled delivery. The drug was immediately released from the core 
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tablet after rupturing, caused by the pressure build up with in the core 
system. Once PEG 6000 was added into the formulation of the outer shell. 
The time lag was shortened with the increase of the amount of PEG used. 
The order of the time lag changed according to weight ratios of the 
EC/PEG 6000 as follows: 
F1 > F2 > F3 > F4 > F5 > F6 > F7 
 The dissolution profile of EC/HEC was also similar to that of the 
dissolution profile of EC/PEG 6000, showing a distinctive inducting lag 
followed by drug release. The time lag of the press coated tablet 
containing 0%, 20%, 40%, 50%, 60%, 80%, 100% of HEC was F8 > F9 > 
F10 > F11 > F12 > F13 > F14 respectively. It is evident that the time lag of 
press-coated tablet changes by varying the amount of EC and PEG 6000 
or HEC in the outer shell. 
 
DISSOLUTION KINETICS 
 In vitro data obtained for glipizide time controlled release tablets 
were used to determine the dissolution kinetics. The drug release data of 
glipizide were fitted to models representing zero order (cumulative amount 
of drug released vs. time), first order (log cumulative percentage of drug 
remaining vs. time), Higuchi’s (cumulative percentage of drug released vs. 
square root of time), and Korsmeyer’s equation (log cumulative 
percentage of drug released vs. log time) kinetics to know the release 
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mechanisms. The data were processed for regression analysis using  
MS-EXCEL statistical functions (table 32). In our study in vitro release 
profiles of drug from all the formulations could be best expressed by 
Higuchi’s equation as the formulations showed highest linearity  
(R2 0.985). This explains why the drug diffuses at a comparatively slower 
rate as the distance for diffusion increases, which is referred to as square 
root kinetics (or Higuchi’s Kinetics). 
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SUMMARY AND CONCLUSION 
 Studies were under taken on the formulation of glipizide time 
controlled release tablets by press coating using hydrophilic polymers 
polyethylene glycol (PEG 6000) and hydroxyl ethyl cellulose (HEC) and 
hydrophobic polymer ethylcellulose. Here EC/PEG was used in the outer 
coating layer for E1 formulation and EC/HEC in outer coating layer for E2 
formulation. 
 The order of dissolution of glipizide from E1 and E2 formulations 
E1 (F1 > F2 > F3 > F4 > F5 > F6 > F7) 
E2 (F8 > F9 > F10 > F11 > F12 > F13 > F14) 
 Chemical incompatibilities study confirmed that there is no 
interaction between drug and excipients in the formulation. The weight 
variations, drug content uniformity, hardness, friability of all the formulated 
tablets were within the specified requirements. Drug release kinetics 
confirmed that the glipizide time controlled release formulations were best 
expressed by Higuchi’s equation. 
 In conclusion, the time lag of press-coated tablet could be 
modulated by choosing the type and amount of excipient used in the outer 
shell to achieve the time-controlled disintegration according to the time 
required The present study indicated that the time lag of the press-coated 
tablet can be suitably modulated by formulating the outer shell with ethyl 
cellulose and polyethylene glycol 6000 or hydroxyl ethyl cellulose. 
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